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Abstract
Murine hepatitis virus (MHV) infection activates the potent antiviral oligoadenylate synthetaseendoribonuclease latent (OAS-RNase L) pathway in myeloid-derived cells of the liver and brain but not in
other cell types in these organs. Canonically, it is thought that upregulation of Oas transcription by type I
interferon (IFN) during virus infection is needed to activate the pathway. However, MHV induces IFN and
upregulate OASs only late in infection, after RNase L has already been activated. The objective of this
thesis work was to determine what role interferon and OAS play in RNase L activation. For this purpose,
bone marrow derived macrophages (BMM) were used that were either fully competent to respond to and
secrete IFN (WT B6), unable to secrete IFN (Ifih1-/-), or not capable of IFN signaling (Ifnar1-/-). It was
found that basal mRNA expression levels of Oas1a, Oas2, and Oas3 in naïve mice were significantly
higher in the liver than in the brain and in myeloid-derived versus non-myeloid derived cells. Furthermore,
activation of RNase L did not require virus-induced IFN, but rather correlated with adequate levels of basal
Oas gene and protein expression, maintained by basal IFN signaling. This suggests that basal levels of
OAS might influence the host’s ability to activate RNase L and restrict MHV infection in an organ-specific
and cell type-specific manner. Data herein demonstrate that myeloid cells are pre-armed with high basal
levels of OAS, sufficient to allow activation of RNase L upon sensing dsRNA early in infection before
interferon signaling develops. This limits virus replication and spread, thus sparing non-myeloid
neighboring cells from infection. Together, these studies have helped define the increasingly complex
interactions between MHV and the type I IFN response.
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ABSTRACT
INTERACTIONS OF THE MURINE CORONAVIRUS MOUSE HEPATITIS
VIRUS WITH THE TYPE I INTERFERON RESPONSE
LESTER DILLON BIRDWELL
AND

SUSAN R. WEISS
Murine hepatitis virus (MHV) infection activates the potent antiviral oligoadenylate
synthetase-endoribonuclease latent (OAS-RNase L) pathway in myeloid-derived cells of
the liver and brain but not in other cell types in these organs. Canonically, it is thought
that upregulation of Oas transcription by type I interferon (IFN) during virus infection is
needed to activate the pathway. However, MHV induces IFN and upregulate OASs only
late in infection, after RNase L has already been activated. The objective of this thesis
work was to determine what role interferon and OAS play in RNase L activation. For this
purpose, bone marrow derived macrophages (BMM) were used that were either fully
competent to respond to and secrete IFN (WT B6), unable to secrete IFN (Ifih1-/-), or not
capable of IFN signaling (Ifnar1-/-). It was found that basal mRNA expression levels of
Oas1a, Oas2, and Oas3 in naïve mice were significantly higher in the liver than in the
brain and in myeloid-derived versus non-myeloid derived cells. Furthermore, activation
of RNase L did not require virus-induced IFN, but rather correlated with adequate levels
of basal Oas gene and protein expression, maintained by basal IFN signaling. This
suggests that basal levels of OAS might influence the host’s ability to activate RNase L
and restrict MHV infection in an organ-specific and cell type-specific manner. Data
herein demonstrate that myeloid cells are pre-armed with high basal levels of OAS,
sufficient to allow activation of RNase L upon sensing dsRNA early in infection before
interferon signaling develops. This limits virus replication and spread, thus sparing nonmyeloid neighboring cells from infection. Together, these studies have helped define the
increasingly complex interactions between MHV and the type I IFN response.
ix

I
CHAPTER ONE
INTRODUCTION
I.1

HISTORICAL PERSPECTIVE

Before 2003, no severe human diseases were attributable to coronaviruses, lending
little to their study. While coronaviruses have been described for more than 50 years
and their replication and pathogenesis have been actively studied since the 1970s,
coronaviruses were only thought to cause the common cold in humans (Pelczar, 2010;
Goldman, 2010). However, some of the animal coronaviruses, such as porcine
transmissible gastroenteritis virus (TGEV), bovine coronavirus (BCoV), and avian
infectious bronchitis viruses (IBV) are of veterinary importance (Saif, 2004). There had
long been speculation about the association of human coronaviruses with more serious
human diseases such as multiple sclerosis, hepatitis, and enteric disease in newborns.
None of these early associations had been substantiated until in 2003, a new human
coronavirus, severe acute respiratory syndrome (SARS-CoV) was linked to a viral
respiratory disease of zoonotic origin. The 2002-2003 outbreak of SARS, which began in
southern China, eventually involved more than 8,000 persons worldwide and was the
first human coronavirus to cause significant disease and economic repercussions (Booth
et al., 2003; Dwosh et al., 2003; Holmes, 2003; Ksiazek et al., 2003; Lee et al., 2003;
Peiris et al., 2003b; Poutanen et al., 2003; Tsang et al., 2003; Varia et al., 2003; WHO,
2003; De Groot, 2013). Another more deadly coronavirus new to humans was identified
in Saudi Arabia in 2012 and associated with Middle East respiratory syndrome (MERSCoV). As of 2015, sporadic cases, small clusters, and large outbreaks of MERS-CoV have
been reported in 26 countries, with over 1600 cases of the virus and over 580 deaths
(WHO, 2015). The occurrence of SARS-CoV and MERS-CoV, which caused severe and life
threatening diseases, reclassified coronaviruses as “emerging” and ignited research on
1

these esoteric pathogens. However, SARS-CoV is classified as a select agent defined as a
biological agent that has been determined to have the potential to pose a severe threat
to both human and animal health. Additionally, most work with MERS-CoV must be
performed in either a Biosafety Level 3 (BSL-3) or an Animal BSL-3 facility using
respective work practices. Consequently, these viruses require specialized handling
beyond the scope of many laboratory settings. Therefore, a murine coronavirus, mouse
hepatitis virus (MHV), has been used to study the pathogenesis and virulence of
coronaviruses. MHV infects several organ systems in laboratory mice providing models
for virus-induced acute encephalitis, hepatitis, pneumonitis, and gastroenteritis in a
natural host. Moreover, infections with MHV provide a model for human disease.

2

I.2

VIRUS CLASSIFICATION AND TAXONOMY

The name "coronavirus" is derived from the Latin corona, meaning crown or halo, and
refers to the characteristic appearance of virions under electron microscopy with a
fringe of large, bulbous surface projections creating an image reminiscent of a royal
crown or of the solar corona. Coronaviruses are part of Group IV of the Baltimore
classification system and are enveloped viruses with a positive-sense RNA genome that
ranges from approximately 26 to 32 kilobases, extraordinarily large for an RNA virus.
Coronaviruses are species in the genera of virus belonging to one of the two subfamilies
Coronavirinae and Torovirinae in the family Coronaviridae. The Coronaviridae,
Arteviridae, Roniviridae, and Mesoniviridae families form the Nidovirales order. The
order Nidovirales is named for the Latin nidus, as all viruses in this order produce a 3' coterminal nested set of subgenomic mRNAs during infection The virus that has the largest
known nonsegmented RNA genome of 31.5 kilobases, MHV, is of the order Nidovirales.
MHV is a prototypical coronavirus of the beta genus. Coronaviruses are divided into four
genera (alpha, beta, gamma, and delta). Betacoronaviruses include viruses that infect
mice and rats as well as other animal species and humans (Enjuanes, 2008; Thiel, 2007;
Balasuriya, 2008; De Vries, 1997). MHV is a group of highly related strains causing a
variety of diseases, such as enteric disease, hepatitis, and respiratory disease, as well as
encephalitis and chronic demyelination. (De Groot, 2011; ICTV, 2010).

3

I.3

MOUSE HEPATITIS VIRUS PATHOGENESIS

Multiple strains of MHV exhibit different tropisms and levels of virulence. The
commonly used laboratory strains such as MHV-A59 used herein infect primarily the
liver and the brain. MHV-A59 infection of mice has been used as an animal model for
studying demyelinating diseases, such as multiple sclerosis. Other strains cause enteric
disease, are spread easily by an oral-fecal route in animal colonies, and are a particular
danger to immunocompromised animals (Barthold, 1993). MHV organ tropism and
virulence is dependent on interactions of viral proteins and host factors and the MHV
model has been used extensively for investigating coronavirus-host interactions,
including elucidating the determinants of tissue tropism and virulence.
MHV-A59 strain is a relatively neuroattenuated, moderately hepatovirulent strain that
was first isolated from a mouse with leukemia in 1961 (Manaker et al., 1961). Although
neuroattenuated compared to the more virulent MHV-JHM strain, A59 causes
demyelination and encephalomyelitis (Lavi, 1984). Central nervous system (CNS) disease
induced by neurotropic MHV strains is divided into two phases, acute encephalitis and
chronic demyelinating disease. Following intracranial or intranasal inoculation, MHV
infects all major CNS cell types including neurons (the most frequently infected cell
type), glial cells (astrocytes, oligodendrocytes, and microglia). Typically, viral titers peak
five days after infection and begin to decline until infectious virus becomes
undetectable approximately two weeks post inoculation (Leparc-Goffart et al. 1998;
Matthews et al. 2001; Roth-Cross, 2008). During this time, infected mice develop mild to
severe encephalomyelitis, characterized by infiltration of a variety of inflammatory cells
into the brain and spinal cord. Innate immune responses are elicited and detectable
within the first few days post infection. These early actions guide and inform the
development of the adaptive immune response (Bergmann et al., 2006; Savarin and
Bergmann, 2008), including the involvement of CD8+ and CD4+ T cells. CD8+ T cells, with
the help of CD4+ T cells, play a dominant role in controlling virus replication and are
4

most numerous in the brain at day seven post infection, coinciding with viral clearance
(Williamson et al., 1991). However, despite clearance of infectious virus, viral RNA, both
genome and mRNA, persist in the CNS and demyelination, largely immune-mediated,
develops, peaking at approximately one month post infection (Elliott et al., 2013; Lavi et
al., 1984; Marten et al., 2001). Additionally, other adaptive immune mediators such as B
cells enter the CNS after other mediators of clearance have initiated, so B cells are not
required for this early process (Navas et al., 2001). However, B cell deficient mice
experience re-emergence of infectious virus in the CNS (Matthews et al., 2002). Despite
clearance of infectious virus, viral RNA persists in the CNS and immune-mediated
demyelination develops and peaks around four weeks post infection. Furthermore, the
degree of viral spread throughout the brain and spinal cord, tropism of virus for
individual CNS cell types, and dissemination of virus to other organs is largely dependent
on viral strain (Weiss and Navas-Martin, 2005).
As stated, MHV-A59 induces acute hepatitis in mice and serves as a model for the
interactions of liver cells and viruses (Weiss and Leibowitz, 2011). After intrahepatic (IH)
inoculation of MHV-A59, viral replication is robust in the liver by three days post
infection (dpi) and peaks at five dpi; inflammation, or hepatitis, peaks after five days and
is mostly cleared by seven dpi (Navas et al., 2001; Roth-Cross et al., 2009).

5

I.4

TYPE I INTERFERON RESPONSE

A generic host defense model has been promulgated for over a century. This model was
strengthened after Elie Metchnikoff recognized and introduced the power of
“phagocytes” to attack and destroy assaulting pathogens (Metchnikoff, 1968).
Furthermore, interferons (IFN) – a group of signaling proteins made and released by
host cells in response to the presence of several pathogens, including viruses – were
discovered in 1957, more than 58 years ago, by Alick Isaacs and Jean Lindenmann when
their experiments on influenza virus and viral interference revealed that an antiviral
factor could “interfere” with viral replication. This ability is attributable to IFNs as they
belong to a large class of proteins known as cytokines that are molecules used for
communication between cells to trigger the protective defenses of the immune system
that help eradicate pathogens (De Andrea, 2002; Cohen, 2001). Since their discovery,
IFNs have been immediately recognized as important components of innate immunity
that activate significant host defense mechanisms with broad specificity (Isaacs and
Lindenmann, I & II, 1957; Lindenmann and Isaacs, 1957). Nonetheless, it was only in
1989 that Charles Janeway articulated a unified view of innate immunity to incorporate
past knowledge and add the concept of pathogen-associated molecular patterns
(PAMPs). Janeway posited that PAMPs were repetitive molecular identifiers that bound
to pattern recognition receptors (PRRs) on ‘innate’ cells of the immune system and
activated them to participate in immune induction and defense (Janeway, 1989).
After infecting a cell, a virus must start to replicate its genome. The viral nucleic acids
produced from this process are typically recognized by different PRRs to activate several
host cell antiviral responses, including the type I IFN response (Kumar et al., 2009).
Infection by many viruses stimulates PRRs through the production of dsRNA. For
example, toll-like receptor 3 is a sensor for double-stranded RNA (dsRNA) in the
endosomal compartment, whereas retinoic acid-inducible gene-I (RIG-I, also known as
DDX58) and melanoma differentiation-associated gene-5 (MDA5, also known as IFIH1)
are activated by dsRNA in the cytosol (Saito, 2008; Schroder, 2005).
6

While RIG-I detects 5’-triphosphorylated dsRNA, MDA5 detects long dsRNA of >2000
base pairs. MDA5 detects and mediates response to a group of positive strand RNA
viruses including encephalomyocarditis virus, murine norovirus, picornaviruses,
polioviruses, and coronaviruses (Gitlin et al., 2006; Kato et al., 2006; McCartney et al.,
2008; Roth-Cross et al., 2008). IFN response to MHV infection is dependent on MDA5
and not on RIG-I.
MDA5 is a cytosolic RIG-I-like helicase. Like RIG-I, MDA5 contains a DExH-box (DECH
variants) helicase domain through which it binds dsRNA and catalyzes hydrolysis of ATP.
MDA5 has a low affinity for its RNA substrate, and may be assisted by Laboratory of
Genetics and Physiology 2 (LGP2), another RIG-I like helicase, to interact with the
adaptor protein mitochondrial antiviral signaling protein (MAVS) (Rodriguez et al., 2014;
Hou et al., 2011; H. Xu et al., 2014b). MAVS, also known as promoter stimulator-1 (IPS1), links both MDA5 and RIG-I to downstream signaling molecules (Jiang et al., 2011;
Kowalinski et al., 2011; Luo et al., 2011; Zeng et al., 2010). Once activated, MAVS
propagates the signal to the cytosolic protein kinase IκB (IKK) and to the transcription
factor nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB). IKK
associates with TANK-binding kinase 1 (TBK1) to phosphorylate and activate the
transcription factor interferon regulatory factor 3 (IRF3) (Yoneyama et al., 2004). These
transcription factors promote transcription of many interferon-stimulated genes (ISGs)
and IFN subtypes.
The products of these ISGs exert numerous antiviral effector functions, many of which
are still not fully described. Recent efforts have been aimed at identifying which ISGs are
antiviral and further characterizing their mechanisms of action. Type I (IFNα/β) and type
III (IL28A, IL28B, IL29) IFNs are often considered the antiviral classes, although type II IFN
(IFNγ) also has well-described antiviral properties (Borden, 2007). Each of these IFNs
induces a unique and partially overlapping set of ISGs (Der, 1998). In addition, some ISGs
7

are directly induced by viral infection in the absence of IFN production (Sen, 2007). This
leads to ISG induction through multiple mechanisms that are intersecting and often selfreinforcing. Collectively, ISGs can target almost any step in a virus life cycle. Some of the
most potent antiviral effectors reinforce the system by further inducing IFN or ISGs.
Other genes enhance or facilitate viral replication, suggesting that some viruses may
have evolved to co-opt IFN effectors for a survival advantage. Independent to the
activation of ISGs, dsRNA sensing by cells also stimulates direct induction of several
genes, via IRFs or NF-κB. These have been termed viral stress inducible genes (Sarkar,
2004) and different dsRNA sensors are involved in their induction.
Type I IFNs, primarily IFNα and IFNβ (Kumar et al., 2009), are produced by infected cells
and act in an autocrine and paracrine manner to induce antiviral activities in both virusinfected cells and neighboring uninfected cells. Innate immune cells, such as
macrophages and dendritic cells (DCs), produce type I IFNs after sensing pathogens. In
particular, plasmacytoid DCs (pDCs) produce large quantities of IFNα. A single IFNβ gene
encodes IFNβ, whereas 14 distinct genes encode various IFNα isoforms in mice (Pestka,
Krause, 2004; Hertzog, 2013; Paludan, 2013; Goubau. 2013; Iwasaki, 2012). Secreted
IFNα and IFNβ bind a heterodimeric transmembrane receptor termed the IFNα receptor
(IFNAR1), which is composed of IFNAR1 and IFNAR2 subunits. In the canonical type I IFNinduced signaling pathway described over 25 years ago, IFNAR engagement was shown
to activate the receptor-associated protein tyrosine kinases Janus kinase 1 (JAK1) and
tyrosine kinase 2 (TYK2), which phosphorylate the latent cytoplasmic transcription
factors STAT1 and STAT2 (Levy, 2002; Stark, 2012). Tyrosine-phosphorylated STAT1 and
STAT2 dimerize and translocate to the nucleus, where they assemble with IFNregulatory factor 9 (IRF9) to form a trimolecular complex called IFN-stimulated gene
factor 3 (ISGF3). ISGF3 binds to its cognate DNA sequences, which are known as IFNstimulated response elements (ISREs), thereby directly activating the transcription of
ISGs. By contrast, most other cytokines activate STAT homodimers that bind to a distinct
gamma-activated sequence (GAS). Thus, canonical type I IFN signaling induces a distinct
8

subset of several hundred ISRE-driven ISGs, many of which establish a cellular antiviral
state. ISG-encoded proteins restrict pathogens by several mechanisms, including the
inhibition of viral transcription, translation, and replication and the degradation of viral
nucleic acids (Stark, 2012; MacMicking, 2012; Schoggins, 2011; Rusinova, 2012).
The IFN response is a broad and early innate host defense against viral infection that is
crucial to survival of mice as evidenced by the extreme susceptibility of IFNAR1
knockout mice to infection with many viruses, including MHV. This genotype of mice,
once infected by MHV-A59 are observed to have enhanced replication in normally
infected organs (brain, liver, and spleen) and increased spread to other organs (heart,
lung, kidney, stomach, and spleen) not normally infected in WT B6 mice. IFNAR1
knockout mice succumb to MHV infection in less than two days (Cervantes-Barragan et
al., 2007; Ireland et al., 2008; Roth-Cross et al., 2008). Cellular responses to IFNAR
ligation are cell type- and context-dependent and vary during the course of an immune
response (van Boxel-Dezaire, 2006; Trinchieri, 2010). This variation results from cell
lineage and developmental differences that alter how cells interpret IFNAR-induced
signals, and from the modulation of IFNAR signaling and ISG expression by concurrent
signals induced by pathogens, PRRs, and immune and environmental factors.
Furthermore, cytosolic receptors for viral RNA have long been recognized. In the 1970s,
biochemical evidence identified the two earliest-discovered and most extensively
studied mediators of the antiviral activity of IFNs, RNase L and protein kinase R (PKR)
(Sadler et al., 2008). Both of these receptors bind to dsRNA but have different
mechanisms of action. Activation of PKR enables the phosphorylation of its substrates,
which include the α subunit of the pivotal translation initiation factor eIF2.
Phosphorylation causes eIF2 to bind irreversibly to the nucleotide exchange factor
eIF2B, thereby preventing recycling of eIF2 and shutting down host cell protein
synthesis. MHV does not lead to eIF2 phosphorylation suggesting that this virus has
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mechanisms that bypass PKR (Koetzner, 2010). Activation of RNase L is discussed in the
following section.
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I.5

OAS-RIBONUCLEASE LATENT

The other potent antiviral IFN-induced activity is the 2’,5’-oligoadenylate synthetaseendoribonuclease latent (OAS-RNase L) pathway (Sadler and Williams, 2008). The OASRNase L axis was one of the first antiviral pathways discovered in the mid-1970s
(Hovanessian, 1977; Clemens and Williams 1978; Kerr and Brown 1978; Ratner, 1978;
Slattery, 1979). RNase L is a highly regulated, latent endoribonuclease first cloned in
1993 when it was referred to as the 2-5A-dependent RNase (Zhou et al., 1993). RNase L
mRNA and protein are constitutively expressed in most, if not all, mammalian tissues
through transcriptional and post-transcriptional mechanisms (Bisbal, et al., 1995; Li et
al., 2000; Zhou et al., 2005). RNase L activity is controlled primarily at the posttranscriptional level by the availability of 2-5A, whose production is dependent on
dsRNA presence in a cell that is sensed by OAS proteins.
OAS proteins are pathogen recognition receptors (PRR) for the viral pathogenassociated molecular pattern – dsRNA. During the lifecycle of MHV, dsRNA is produced
in the cytosol of cells, which is sensed by OAS proteins. Once stimulated by dsRNA, OAS
uses ATP to synthesize 2-5A molecules of the formula [px5ʹA(2ʹp5ʹA)n; x = 1–3; n > 2],
yielding a 5ʹ-triphosphorylated triadenylate with 2’,5’-phosphodiesterase linkages. Mice
express several OAS proteins that produce 2-5A, including OAS1A/G, OAS2, OAS3 as well
as OASL2 (Kakuta, Shibata, & Iwakura, 2002; Kalinichenko et al., 2004; Mashimo et al.,
2003). The concentration of 2-5A is believed to be the primary factor controlling RNase L
activation. At subnanomolar levels, 2-5A binds to the ubiquitous cellular RNase L,
causing inactive RNase L monomers to form activated dimers (Dong and Silverman,
1995). Active RNase L cleaves single-stranded RNA (ssRNA) in uracil-rich sequences,
typically after double uracil or uracil-adenosine dinucleotides (Floyd-Smith, 1981;
Wreschner, 1981b).
The RNase L antiviral mechanism varies, depending on the types of RNA molecules that
are cleaved. If the RNA substrate for RNase L is viral genomic single-stranded RNA, even
11

a single cleavage event per viral genome might prevent replication. Cleavage of viral
mRNA is a mechanism that could potentially apply to RNA and DNA viruses with
different replication strategies. Indeed, the antiviral activity of the OAS-RNase L pathway
has been demonstrated during infections of mice with numerous RNA and DNA viruses
(Flodström-Tullberg et al., 2005; Li et al., 1998; Samuel et al., 2006; Scherbik et al., 2006;
Washenberger et al., 2007; Xiang et al., 2002; Zhou et al., 1997).
In addition, degradation of cellular RNA, including rRNA in intact ribosomes, could
damage host cell machinery required for protein synthesis (Li, 2004; Silverman, 1983).
Also, RNase L restricts viral infections by causing apoptosis through an unknown
mechanism involving Jun N-terminal kinase (JNK) (Zhou, 1997; Li, 2004; Castelli, 1997).
Furthermore, RNase L activation results in autophagy in a pathway involving JNK and
protein kinase R (PKR) that can either enhance or decrease viral replication (Chakrabarti,
2012; Siddiqui, 2012). Finally, effects of the OAS-RNase L pathway extend beyond
initially infected cells to support a prolonged antiviral state in some cell types and
organisms through further induction and section of IFN by the small RNAs created as
products of RNase L digestion (Malathi, 2007; Silverman, 2007).
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1.6

ANTAGONISM OF THE RNASE L PATHWAY

In response to cellular defenses such as the host type I IFN response, viruses have
evolved countermeasures. Viruses from diverse families express proteins that block IFN
induction and signaling pathways, such as the PKR and OAS-RNase L pathways. This was
reinforced by studies of mice deficient in these pathways that revealed enhanced
sensitivity to infection by a range of viruses. However, although these antiviral
mechanisms were clearly important at both a cellular and an organismal level, they did
not account for the development of a virus-specific immune response.
Indeed, while there were no significant differences in viral titers or pathology in the
livers of A59-infected B6 and Rnasel−/− mice during early infection, later timepoints
revealed that the livers of infected Rnasel−/− mice have significant titers of virus, antigen
expression, and pathology, implying that Rnasel−/− mice are defective in viral clearance.
One possible reason for the delay in clearance is that Rnasel−/− mice have lower levels of
apoptosis and in addition are relatively resistant to apoptosis, resulting in increased
numbers of cells in the thymus and spleen (Zhou et al., 1997). However, Rnasel−/− mice
are eventually able to clear virus (Zhao et al., 2012).
The aforementioned studies underscore the importance of RNase L and its activities
during MHV infection. Indeed, many viruses antagonize RNase L and its effects. For
example, encephalomyocarditis virus (EMCV) (Zhou, 1993), herpes simplex virus-1 (HSV1) (Austin, 2005; Zheng, 2001), vaccinia virus (VV) (Diaz-Guerra, 1997), coxsackie B4
virus (Flodstrom-Tullberg, 2005), West Nile virus (Samuel, 2006), Theiler’s virus (TMEV)
(Sorgeloos, 2013), and Coronaviruses (Cruz, 2011; Zhao, 2012) inhibit antiviral activity of
the OAS-RNase L pathway by expressing antagonizing proteins that are in some cases
vital for viral replication and pathogenesis (Randall & Goodbourn, 2008; Silverman,
2007; Zhou et al., 1997)). One of the most common and well-characterized mechanisms
of IFN antagonism is the binding and sequestering of dsRNA by proteins such as VV pE3L
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(Chang et al., 1992; Xiang et al., 2002), influenza virus NS1 (Lu et al., 1995; Min and Krug,
2006), reovirus σ3, and HSV-1 pUS11 (Schneider, 2003). Binding to these proteins
appears to neutralize the ability of dsRNA to activate cellular antiviral responses,
including activation of RNase L.
Another strategy of OAS-RNase L pathway antagonism is direct inhibition of RNase L
activation. For example, human immunodeficiency virus (Martinand et al., 1999) and
EMCV (Martinand et al., 1998) induce expression of an RNase L inhibitor protein, RLI
(a.k.a. ABCE1). Group C enterovirus has a conserved RNA structure that inhibits the
activity of RNase L (Townsend et al., 2008). HSV-1 (Cayley et al., 1984) and Simian
vacuolating virus 40 induces synthesis of 2-5A derivatives that antagonize or fail to
activate RNase L. The L* of TMEV directly inhibits RNase L (Michiels, 2013).
Among these direct forms of RNase L antagonism, MHV has evolved a unique
mechanism mediated by nonstructural protein 2 (ns2). The ns2 protein has 2ʹ,5ʹphosphodiesterase (PDE) activity that specifically cleaves 2’,5’ phosphodiester bonds
and converts 2-5A into ATP and AMP. Cleavage of 2-5A by ns2 profoundly limits the
extent of RNase L activation thereby enhancing viral growth and viral pathogenesis
(Zhao, 2012). Furthermore, ns2 is dispensable for virus replication in transformed cell
lines but serves as an IFN antagonist and is required for the induction of hepatitis in vivo
(Zhao, 2012). As a member of group II (eukaryotic LigT) 2H-phosphoesterase
superfamily, ns2 contains two HxT/S (H, histidine; T, threonine; S, serine; x, any amino
acid) catalytic motifs. This group contains cellular proteins such as A-kinase-anchoring
protein-7 (AKAP7) and viral proteins, including VP3 of group A rotavirus, polypeptide 1a
of torovirus (Mazumder, 2002), and NS4b of MERS-CoV (unpublished). Introduction of
amino acid substitutions into the predicted catalytic histidine residues (Roth-Cross et al.,
2009) attenuates MHV-A59 replication in the liver and reduces hepatitis to a minimal
level without affecting viral replication in the brain or without reducing encephalitis
(Roth-Cross et al., 2009). This mutant strain is known as ns2H126R. This mutant strain
14

expresses an enzymatically inactive ns2 with a histidine-to-arginine amino acid
substitution at position 126. In conjunction with the WT MHV-A59 strain, the ns2H126R
mutant strain is used extensively throughout this thesis and is used to elucidate the
organ-specific and cell type-specific nature of RNase L antagonism during MHV
infection.
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I.7

AIMS OF DISSERTATION

MHV differs from many other viruses in that it stimulates type I IFN production in only
limited cell types, primarily in macrophages (Roth-Cross et al., 2008) and plasmacytoid
dendritic cells (Cervantes-Barragan et al., 2007). Furthermore, MHV displays cell-type
specific sensitivity to the antiviral effects of IFN treatment, with macrophage lineage
cells being most successful in restricting MHV replication (Rose and Weiss, 2009; Zhao et
al., 2011). Additionally, in contrast to its infection of the liver, ns2H126R can replicate
efficiently, to a similar extent as MHV-A59 in the CNS of B6 mice, as well as in cell lines
and some primary cells (Zhao et al. , 2011). These observations suggest that MHV has
evolved mechanisms to antagonize the IFN response in a cell type-specific and organspecific fashion, which may influence pathogenesis in vivo. It is unclear why RNase L
activation is organ- and cell-type specific and most robust in myeloid-derived cells. This
thesis aims to investigate the mechanisms underlying activation of the OAS-RNase L
pathway and its antagonism by a virus induced phosphodiesterase.
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II
CHAPTER TWO
CELL-TYPE SPECIFIC ACTIVATION OF THE OLIGOADENYLATE SYNTHETASERNASE L PATHWAY BY A MURINE CORONAVIRUS

This chapter appeared as a published peer-reviewed article titled “Cell-type specific
activation of the oligoadenylate synthetase-RNase L pathway by a murine coronavirus”
by L. Zhao, L. Dillon Birdwell§, A. Wu, R. Elliott, K. M. Rose, J. M. Phillips, Y. Li, J.
Grinspan, R. H. Silverman, and S. R. Weiss. Journal of Virology, 2013.
§

LDB and LZ contributed equally to this work.
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II.1

ABSTRACT

Previous studies have demonstrated that the murine coronavirus mouse hepatitis virus
(MHV) nonstructural protein 2 (ns2) is a 2’, 5’-phosphodiesterase that inhibits activetion of the interferon-induced oligoadenylate synthetase (OAS)-RNase L pathway.
Enzymatically active ns2 is required for efficient MHV replication in macrophages, as
well as for the induction of hepatitis in C57BL/6 mice. In contrast, following intranasal or
intracranial inoculation, efficient replication of MHV in the brain is not dependent on an
enzymatically active ns2. The replication of wild-type MHV strain A59 (A59) and a
mutant with an inactive phosphodiesterase (ns2H126R) was assessed in primary
hepatocytes and primary central nervous system (CNS) cell types—neurons, astrocytes,
and oligodendrocytes. A59 and ns2H126R replicated with similar kinetics in all cell types
tested, except macrophages and microglia. RNase L activity, as assessed by rRNA
cleavage, was induced by ns2H126R, but not by A59, and only in macrophages and
microglia. Activation of RNase L correlated with the induction of type I interferon and
the consequent high levels of Oas mRNA induced in these cell types. Pretreatment of
nonmyeloid cells with interferon restricted A59 and ns2H126R to the same extent and
failed to activate RNase L following infection, despite induction of Oas expression.
However,

rRNA

degradation

was

induced

by

treatment

of

astrocytes

or

oligodendrocytes with poly(I:C). Thus, RNase L activation during MHV infection is cell
type specific and correlates with relatively high levels of expression of Oas genes, which
are necessary but not sufficient for induction of an effective RNase L antiviral response.

18

II.2

INTRODUCTION

The murine coronavirus, mouse hepatitis virus (MHV), is an enveloped, positive-strand
RNA virus of the coronavirus family, within the nidovirus order. MHV is a collection of
strains with tropisms for different organs, including the liver and central nervous system
(CNS), and thus provides models for the study of acute encephalitis and hepatitis as well
as chronic demyelinating disease. The MHV-A59 strain (A59) used in this study induces
mild encephalitis and moderate hepatitis. Studies of the pathogenesis of MHV strains
and recombinant chimeric MHVs have shown that post entry virus–host interactions
have significant impact on organ tropism and virulence in MHV infected mice (Navas &
Weiss, 2003; Zhao, Rose, Elliott, Van Rooijen, & Weiss, 2011).
The type I IFN response is an early innate response that is crucial to survival of mice
following infection with many viruses, including MHV (Cervantes-Barragan et al., 2007;
Ireland, Stohlman, Hinton, Atkinson, & Bergmann, 2008; Roth-Cross, Bender, & Weiss,
2008). During infection, viral dsRNA is recognized by pattern recognition receptors, such
as MDA5 in the case of MHV in most cell types (Cervantes-Barragan et al., 2007; Ireland
et al., 2008; Roth-Cross et al., 2008); this leads to the synthesis of type I IFN (Figure 2.1).
IFNα, β induces expression of interferon-stimulated genes (ISGs) encoding pattern
recognition receptors, transcription factors, and antiviral effectors, including multiple
oligoadenylate synthetase (OAS) proteins. Viral dsRNA directly binds to and activates
OAS to synthesize 2’, 5’-linked oligoadenylates (2-5A), which induce RNase L
dimerization and activity (Dong & Silverman, 1995; Malathi, Dong, Gale, & Silverman,
2007; Silverman, 2007). RNase L is a particularly potent antiviral effector in that it both
directly cleaves viral and host RNA, thereby reducing the amount of viral RNA available
for replication and packaging of genome into progeny virus, and inhibits host and viral
protein synthesis. In addition, RNase L-mediated cleavage generates additional small
RNAs that can be recognized by cytoplasmic pattern recognition receptors, further
amplifying IFN synthesis (A. Zhou et al., 1997). Importantly and unlike most other IFN
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induced activities, activation of the OAS-RNase L pathway requires both viral infection
(production of ds RNA) and type I IFN exposure (upregulation of OAS) in the same cell in
order to produce sufficient 2-5A to activate RNase L.
Many viruses, including MHV, have evolved mechanisms to avoid and/or antagonize
host type I IFN responses (Randall & Goodbourn, 2008), including the OAS-RNase L
pathway (Silverman, 2007; A. Zhou et al., 1997). We have shown previously that the A59
accessory protein ns2 is a type I IFN antagonist. ns2 has 2’, 5’-phosphodiesterase activity
that cleaves 2-5A, thereby antagonizing the activation of the OAS-RNase L pathway
(Zhao et al., 2012). An ns2 mutant of A59 (ns2H126R), expressing an inactive
phosphodiesterase, was unable to replicate efficiently in macrophages derived from B6
mice, indicating that an active ns2 is required for robust replication of A59 in that cell
type. However, ns2H126R was able to replicate efficiently in macrophages derived from
mice deficient in either type I interferon receptor expression (Ifnar1-/-) mice or RNase L
expression (Rnasel-/-) (Zhao et al., 2012; Zhao et al., 2011). These and other published
data (Zhao et al., 2012; Zhao et al., 2011) led us to conclude that ns2 antagonizes IFN
signaling, by downregulating RNase L activation. Furthermore, in vivo, ns2 acts an organspecific virulence factor that is required for efficient hepatic virus replication and
pathology in B6 mice (Roth-Cross et al., 2009; Zhao et al., 2011). Macrophage depletion
promoted the replication of ns2H126R in the liver to a level close to that of wild type virus.
This observation emphasizes the crucial role of the type I IFN response in macrophages
in protecting the host from MHV induced hepatitis (Zhao et al., 2011).
In contrast to its infection of the liver, ns2H126R can replicate efficiently, to a similar
extent as A59 in the central nervous system (CNS) of B6 mice, as well as in cell lines and
some primary cells (Zhao et al., 2011). Here, we have further investigated the
mechanisms underlying the organ and cell type specific requirements for ns2-mediated
IFN antagonism in the efficient replication of MHV. We have compared the Oas mRNA
expression levels as well as the replication of A59 and ns2H126R between the liver and the
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brain and among macrophages and brain and liver parenchymal cell types. Our data
suggest that activation of the OAS-RNase L pathway depends in part on the levels of
expression of Oas genes. Furthermore, activation of this pathway is most robust in
myeloid lineage cells and successful replication in myeloid cells is a pre-requisite for
replication in the liver but not in the CNS.
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II.3

OBSERVATIONS

II.3.i

MHV replication depends on ns2-phosphodiesterase activity in an organ
specific manner

MHV strain A59 infects predominantly the central nervous system (CNS) and the liver,
resulting in mild encephalitis and moderate hepatitis (Weiss & Leibowitz, 2011). We
have shown previously that amino acid substitution at either of the predicted catalytic
phosphodiesterase residue, H46A or H126R, of the A59 ns2 protein confers attenuation
of viral replication and pathogenicity in the liver but not in the brain of C57BL/6 (B6)
mice (Zhao et al., 2011). We have now compared replication of wild type A59 and
mutant ns2H126R in the brain and liver between Rnasel-/- mice and B6 mice by quantifying
the infectious viral titers in each organ 5 days following intracranial inoculation with 200
PFU/mouse of each virus, which corresponds to the peak of viral infection (Figure 2.2A).
The infectious virus titers did not differ significantly between the brains of B6 and
Rnasel-/- mice infected with either A59 or mutant ns2H126R. In contrast, titers of ns2H126R
were more than 100-fold lower than those of A59 (p = 0.0052) in the livers of infected
B6 mice at 5 dpi, consistent with previously observed results of intrahepatic inoculation
(Zhao et al., 2012; Zhao et al., 2011). The titers of ns2H126R and A59 in the livers of
Rnasel-/- mice were not significantly different, further illustrating the role of ns2 as an
antagonist of RNase L activation.
We reasoned that host defenses might be higher when virus enters the brain by a more
natural route of infection (Fensterl et al., 2012). Thus, to further investigate the
requirement for ns2 expression for MHV replication in the CNS, B6 mice were infected
intranasally with 2x105 PFU A59 or ns2H126R and the virus titers in the brain and liver 5
dpi were quantified (Figure 2.2B). Again, the titers in the brain did not differ significantly
between A59 and ns2H126R infected mice 5 dpi, while the titers of A59 in the liver were
significantly greater than that of ns2H126R (p = 0.0006). The A59 titers in the liver were
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approximately 1000 fold higher than the minimal titers of ns2H126R. Thus, dispensability
of ns2 activity for replication in the brain was independent of the route of inoculation.
RNase L activation depends on the level of 2-5A, which is produced by several OAS
proteins upon activation by viral dsRNA. We used quantitative reverse transcriptase-PCR
(qRT-PCR) to compare the basal levels of expression of three active Oas genes, Oas1a,
Oas2 and Oas3, between the brain and liver of uninfected B6 mice (Zhao et al., 2012) (2.
2C). We found that the basal mRNA expression levels of Oas1a, Oas2, and Oas3 in naïve
mice were significantly higher in the liver than in the brain, as we reported previously
for other IFN-induced genes (Zhao et al., 2011). This suggests that basal levels of OAS
might influence the host’s ability to activate RNase L and restrict MHV infection in an
organ-specific manner. The levels of RNase L mRNA expression were similar between
the brain and liver (Figure 2.2C) and do not likely contribute to the differences in the
effects of viral phosphodiesterase activity.
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II.3.ii

Efficient replication of MHV in hepatocytes does not require antagonism of the
OAS-RNase L pathway

We previously observed that macrophages, unlike transformed fibroblast cell lines and
other primary cell types tested, restrict replication of more effectively than that of A59
and that in vivo depletion of macrophages allowed to cause hepatitis in B6 mice (Zhao et
al., 2011). Based on these data, we hypothesized that liver parenchymal cells were less
well prepared than macrophages to restrict MHV. To test this hypothesis, we compared
replication of A59 and ns2H126R in hepatocytes, the most abundant cell type in the liver
parenchyma, and in macrophages. Primary hepatocyte cultures (Figure 2.3A) and bone
marrow derived macrophages (BMM) (Figure 2.3B) were infected with A59 or ns2H126R,
and the replication kinetics were compared between the isolates for each cell type.
While BMM severely restricted ns2H126R replication relative to A59, both viruses
replicated with similar kinetics and to similar final titers in primary hepatocytes. In
addition, both viruses produced syncytia in hepatocytes, as observed by staining the
cultures with an antibody directed against the MHV nucleocapsid protein (Figure 2.3C).
We next compared the effects of IFN pretreatment on replication of A59 and ns2H126R in
hepatocytes. Cultures were treated with 100 U/ml of IFNα for 24 hours before infection.
Virus was quantified from the supernatant at several times post infection. IFN treatment
of hepatocytes decreased viral titers 100-fold relative to control wells by 16 hpi (Figure
2.3D). However, ns2H126R and A59 replicated to similar levels in IFN-treated cells,
indicating that IFN treatment of hepatocytes induces a robust anti-MHV response that is
not dependent on RNase L activation. Consistent with this observation, RNase Lmediated degradation of ribosomal RNA (rRNA) was not detected in hepatocytes
infected with A59 or ns2H126R, as assessed by Bioanalyzer analysis (described in
Experimental Framework and Notation) (Figure 2.3E).
We reasoned that an adequate level of expression of OAS, the producer of 2-5A, would
be a requirement for the activation of RNase L and furthermore, that the level of OAS
could vary among cell types. To further investigate the mechanisms underlying the
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difference in RNase L activation between macrophages and hepatocytes, we compared
the basal levels of expression of several genes encoding active OAS proteins and found
that Oas mRNAs levels were 100 to 1000-fold higher in macrophages than in
hepatocytes (Figure 2.4A). Even following MHV infection, at 16 hpi, Oas1a mRNA levels
remained comparatively low in hepatocytes relative to macrophages (Figure 2.4B). In
addition, while MHV infection of BMM significantly induced IFNβ mRNA expression at 16
hpi relative to mock infection, mRNA levels remained low in infected hepatocytes
(Figure 2.4C). Similar to the pattern of Oas mRNA expression, the basal levels of ISG
mRNAs encoding a group of pattern recognition receptors, transcription factors and
antiviral genes involved in the host response to viruses (Figure 2.4D) were also higher in
BMM than in hepatocytes, which may in part explain the weak induction of IFNβ mRNA
in hepatocytes relative to BMM. The level of RNase L mRNA was not significantly
different in BMM and hepatocytes (data not shown).
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II.3.iii MHV replication is restricted by the OAS-RNase L antiviral pathway in microglia
but not in neurons, astrocytes, or oligodendrocytes
As shown above, antagonism of RNase L is not required for efficient MHV replication in
the brain. Thus, we investigated the ability of each of the major CNS cell types to restrict
A59 and ns2H126R infection (Figure 2.5). Primary cultures of hippocampal neurons,
oligodendrocytes, astrocytes and microglial were each prepared as described in the
Materials and Methods and previously (Bender, Phillips, Scott, & Weiss, 2010;
Feigenson, Reid, See, Crenshaw, & Grinspan, 2009; Roth-Cross et al., 2008). Cultures
were infected at an MOI of 1 PFU/cell and cells harvested at optimal times post
infection for assessing growth kinetics of the virus in each cell type. There were no
significant differences in the titers between A59 and ns2H126R in neuron (Figure 2.5A),
oligodendrocyte (Figure 2.5B), or astrocyte (Figure 2.5C) cultures at the times examined.
However, in microglia (Figure 2.5D), the titer of ns2H126R was 10-fold lower than that of
A59 at 24 hours post infection. Thus, like BMM, microglia preferentially restricted
ns2H126R. Furthermore, ns2H126R replicated to the same extent as A59 in microglia derived
from Rnasel-/- mice (Figure 2.5E), indicating that restriction of ns2 mutant virus in B6
microglia was due to activation of RNase L, as observed previously in BMM (Zhao et al.,
2012; Zhao et al., 2011; H. Zhou, Zhao, & Perlman, 2010).
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II.3.iv Activation of RNase L activity correlates with high basal and induced levels of
Oas genes and IFN signaling
To investigate the possibility that the basal levels of ISGs contribute to and/or predict
viral restriction, we quantified the basal mRNA expression levels of Oas genes (Figure
2.6A) as well as a selection of other ISGs (Figure 2.6B) in the major cell types of the CNS
parenchyma. The levels of basal ISG mRNA (Figure 2.6A&B) were greater in microglia
than in other CNS cell types, as might be expected for cells of macrophage lineage. The
basal levels of ISG mRNAs, especially the Oas mRNAs, expressed in neurons and
oligodendrocytes, (Figure 2.6A), were low, near the limit of detection and at least 100 to
1000-fold lower than in microglia, while astrocytes expressed intermediate mRNA
levels. Next, we examined the Oas mRNA levels after viral infection of these CNS cells
types (Figure 2.6C). At 24 hours post infection with A59 or ns2H126R, the Oas mRNA levels
in neuron and oligodendrocyte cultures were still at or near the limit of detection by
qRT-PCR, indicating that MHV does not directly induce the expression of Oas in these
two cell types. However, in astrocytes and microglia, infection induced significant upregulation of Oas mRNAs, up to 50-fold for Oas2. However, the levels in astrocytes were
still 10 to 100-fold lower than in microglia. A59 and ns2H126R elicited similar levels of
induction.
We reasoned that the lack of preferential restriction of ns2H126R in CNS cell types other
than microglia was due to sub-optimal levels of OAS leading to insufficient production of
2-5A and the consequent lack of activation of RNase L. In order to assess directly the
degree of RNase L activity induced during infection of CNS cells, we compared the
extents of rRNA cleavage in neurons, oligodendrocytes, astrocytes, and microglia
infected at 24 hpi with either ns2H126R or A59 (Figure 2.7A). Bioanalyzer analysis of RNA
from infected cells showed that neither virus induced detectable rRNA cleavage in
neurons, oligodendrocytes, or astrocytes, consistent with the lack of preferential
restriction of ns2H126R in these cell types. In contrast, ns2H126R, but not A59, induced
rRNA cleavage in microglia.
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We had observed that MHV failed to induce expression of type I IFN in many cell types
(Roth-Cross et al., 2008; Roth-Cross, Martinez-Sobrido, Scott, Garcia-Sastre, & Weiss,
2007) and hypothesized that low Oas mRNA levels in MHV infected primary cultures
(Figure 6C) could be attributed to insufficient IFN production. Indeed, analysis of IFNβ
mRNA levels by qRT-PCR showed that induction by both A59 and ns2H126R was more
than 100-fold greater in microglia than in the other cell types tested (Figure 2.7B). A
bioassay for anti-viral activity (Figure 2.7C) confirmed that both A59 and ns2H126R
induced detectable IFN expression in microglia, but not in other cell types. Thus, these
data suggest that activation of the OAS-RNase L pathway correlates with the ability of
MHV to induce IFN production and underscores the requirement for simultaneous type I
IFN signaling and viral infection in cells with low basal Oas mRNA levels.
To assess the effects of IFN pretreatment of cells on ISG mRNA level and replication of
A59 and ns2H126R, primary CNS cultures were pretreated with IFNα (100 U/ml). At 24 h
post treatment, Oas mRNA expression, as quantified by qRT-PCR, was significantly
induced in all cell types as expected; the Oas1a and Oas2 mRNAs levels in
oligodendrocytes were similar to those in microglia (Figure 2.8A). We then assessed
replication of A59 and ns2H126R in each cell type following IFN pretreatment. IFN
pretreatment severely restricted A59 replication in all neural cell types, up to 1000-fold
in microglia, 100-fold in astrocytes and oligodendrocytes and 10-fold in neurons (Figure
2.8B-E), indicating induction of IFN-dependent antiviral activities. As reported previously
(Zhao et al., 2011), ns2H126R displayed enhanced sensitivity to IFN pretreatment in
microglia similar to that in BMM (Figure 2.8E), implying that RNase L had been activated.
In contrast, ns2H126R displayed similar sensitivity to IFN as A59 in neurons,
oligodendrocytes and astrocytes (Figure 2.8B-D), suggesting that RNase L had not been
activated despite the increase in Oas levels following IFN treatment.
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II.3.v

Several other viruses also fail to activate RNase L in astrocytes, while poly (I:C)
activates RNase L in astrocytes and oligodendrocytes

In order to determine whether the failure to activate RNase L in neurons, astrocytes and
oligodendrocytes was a characteristic of these cell types or specific to MHV, we infected
astrocytes with three other viruses, encephalomyocarditis virus (EMCV) (Hoskins &
Sanders, 1957), LaCrosse virus (LACV) (Thompson, Kalfayan, & Anslow, 1965), and
Sendai virus (SeV) (Basler et al., 2003). (EMCV and LACV are neurotropic, while SeV is
pneumotropic.) We had found that RNase L restricted both SeV and EMCV in
macrophages (Zhao et al., 2012) and that SeV induced IFNβ in astrocytes (Roth-Cross et
al., 2008). However, like A59 and ns2H126R, EMCV, SeV, and LACV all failed to induce
RNase L mediated degradation of rRNA in astrocytes (Figure 2.9A), indicating that the
failure to activate RNase L in astrocytes is not specific to MHV.
We next investigated whether neurons or astrocytes, which did not exhibit RNase Lmediated rRNA degradation in the context of viral infection, can regulate RNase L
activity in response to poly (I:C). Poly (I:C) serves as a surrogate for dsRNA for both the
induction of type I IFN expression and the activation of OAS. We treated primary neuron
and astrocyte cultures with IFNα and transfected them with poly (I:C). RNA was
extracted from treated cells 6 hours after poly (I:C) treatment and analyzed for the
degradation of rRNA. rRNA degradation was evident in both cultures indicating that
RNase L was activated (Figure 2.9B). Thus, astrocytes and neurons have the potential to
upregulate RNase L activity, but this pathway is not activated during infection with a
variety of viruses including ns2H126R mutant expressing an inactive phosphodiesterase
(Figure 2.9B).
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II.3.vi Cerebellum and spinal cord regions activate RNase L during MHV infection
To assess infection of mouse brains during MHV infection, we intranasally or
intracranally infected WT or Rnasel-/- with 100,000 PFU/mouse or 200 PFU/mouse,
respectively. After five days of infection, we harvested different brain regions. These
regions were grossly measured and labeled as the following: olfactory bulb, cortex,
cerebellum, brain stem, and spinal cord. Virus replication of either WT A59 or mutant
strain from these mouse brain sections were compared. In both the intranasal (Figure
2.10A) and intracranial (Figure 2.10C) experiments, the replication of each strain is
similar between every brain region except in the spinal cord and the cerebellum. In
these regions, mutant virus replication is significantly less than WT A59 replication
levels. Furthermore, this replication decrease can be attributed to RNase L activation as
levels of replication of the mutant virus strain are not significantly different from WT
A59 replication in Rnasel-/- mice (Figure 2.10B). As assessed by RNA degradation, only
the cerebellum and spinal cord show observable degradation products during ns2
mutant infection that is specific to RNase L (Figure 2.10E&F). Additionally, there are no
significant differences in the basal mRNA expression levels of the Oas genes as
measured by qPCR (Figure 2.10D).
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Figure 2.1. Canonical type I IFN induction and signaling pathway. (Grey) MHV RNA is
recognized by MDA5 leading to expression of IFNβ. IFNβ mediates transcription of
antiviral ISGs. (Black) OAS-RNase L pathway. dsRNA activates OAS which synthesizes 25A. This oligonucleotide activates RNase L to degrade viral and cellular RNA. MHV ns2
can degrade 2-5A.
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Figure 2.2. Replication of A59 and ns2H126R in the liver and the brain of B6 and Rnasel-/mice. (A) B6 and Rnasel-/- mice were inoculated intracranially with 200 PFU/mouse of
A59 or ns2H126R (n=5). Mice were sacrificed at 5 dpi, brains and livers harvested and virus
titered by plaque assay. (B) B6 and Rnasel-/- were inoculated intranasally with 200,000
PFU/mouse of A59 or ns2H126R (n=5). Mice were sacrificed at 5 dpi, brains and livers
harvested and virus titered by plaque assay. (C) RNA was extracted from the livers and
brains of uninfected mice (n=5); expression levels of Oas1a, Oas2, Oas3, and RNase L
mRNA were assessed by qRT-PCR. mRNA expression levels relative to β-actin mRNA
were expressed as 2–ΔCT, (ΔCT = CT（gene of interest）–CT（β-actin）). The data are from one
representative of two experiments performed and are shown as the means ± the SEM.
***, p < 0.001.
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Figure 2.3. Replication of A59 and ns2H126R in primary hepatocytes. (A) Primary
hepatocyte or (B) BMM cultures were infected with A59 or ns2H126R (1 PFU/cell); at the
times indicated virus was titered from the supernatant. (C) Primary hepatocyte cultures
were infected with A59 or ns2H126R (1 PFU/cell; at 16 hpi, cells were stained with DAPI to
locate cellular nuclei (blue) and an antibody directed against MHV nucleocapsid protein
to visualize virus (green). Cultures were examined under a Nikon Eclipse 2000EUﬂuorescence microscope. (D) Primary hepatocyte cultures were treated with 100 U/ml
IFN for 24 hours, then infected with A59 or ns2H126R and treated as in panel A.
Hepatocytes used in panels A and D were prepared from the same mouse. (E) RNA was
extracted from infected hepatocytes and BMM (16 hours post infection) and ribosomal
RNA (rRNA) degradation was assessed by Bioanalyzer. The data are from one
representative of two experiments. The growth curves were performed in BMM in
triplicate and in hepatocytes in duplicate. **, p < 0.01; ***, p < 0.001
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Figure 2.4. Oas and IFNβ mRNA expression in hepatocytes and BMM. (A) RNA was
extracted from BMMs and hepatocytes and basal levels of Oas1a, Oas2 and Oas3 mRNA
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expression were quantified by qRT-PCR. (B) Hepatocytes and BMM were infected with
A59 or ns2H126R (1 PFU/cell); RNA was extracted at 16 hpi and Oas1a mRNA expression
was quantified by qRT-PCR (C) Ifnβ1 mRNA levels were quantified by qRT-PCR using the
same RNAs as in panel B. (D) Basal levels of ISG mRNAs, including MDA5, STAT1, IRF7,
IFIT1, and ISG15, were quantified in BMMs and hepatocytes by qRT-PCR. The mRNA
expression levels relative to β-actin mRNA were expressed as 2–ΔCT, (ΔCT = CT（gene of interest
）– CT（β-actin）). The data are from one representative of two experiments, performed in
triplicate and are shown as the means ± the SEM.
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Figure 2.5. Infection of primary neural cells with A59 and ns2H126R. Primary cell cultures
of (A) neurons, (B) oligodendrocytes, (C) astrocytes, (D) microglia, and (E) Rnasel-/microglia were infected with A59 and ns2H126R (1 PFU/cell). Virus was titered from the
supernatant at the times indicated. The data are from one of two replicate experiments
(panel E, one experiment) performed in triplicate and are shown as the means ± the
SEM. **, p < 0.01.
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Figure 2.6. Oas mRNA expression in primary neural cell cultures. (A) RNA was extracted
from neurons, oligodendrocytes, astrocytes and microglia and Oas1a, Oas2, and Oas3
mRNA expression levels quantified by qRT-PCR. (B) MDA5, RIG-I, STAT1, IRF-7, IFIT1,
IFIT2 and ISG15 mRNA levels were quantified from the same RNAs as in panel A. (C)
primary cell cultures were infected with A59 or ns2H126R or mock infected; at 24 hpi RNA
was extracted and Oas1a mRNA quantified. mRNA expression levels relative to β-actin
mRNA were expressed as 2–ΔCT, (ΔCT = CT（gene of interest）–CT（β-actin）). The data are from
one representative of two experiments performed in triplicate and are shown as the
means ± the SEM.
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Figure 2.7. RNase L activity and IFNβ expression following infection of primary neural
cells. (A) Primary neuron, oligodendrocyte, astrocyte and microglia were infected with
A59 and ns2H126R (1 PFU/cell). RNA was harvested 24 hpi and analyzed for rRNA
degradation by Bioanalyzer. Positions of 28S and 18S rRNA are indicated. (B) IFNβ mRNA
expression was quantified in RNAs prepared from infected cultures as in panel A. mRNA
expression levels relative to β-actin mRNA were expressed as 2–ΔCT (ΔCT = CT（gene of interest)
– CT（β-actin）). (C) Supernatants from primary CNS cultures as in panel A were treated with
ultraviolet light and incubated with L2 mouse ﬁbroblast cells for 24 h, followed by
infection with NDV-GFP (1 PFU/cell). As a positive control, L2 cells were treated with
IFNα alpha for 24 h and then infected with NDV-GFP. At 24 hpi, cells were examined
under a Nikon Eclipse 2000E-Uﬂuorescence microscope.
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Figure 2.8. Oas mRNA expression and virus replication in primary neural cell cultures
following IFNα treatment. (A) Primary cell cultures were treated (or mock treated) with
100 U/ml of IFNα for 24 hours. RNA was extracted and expression levels of Oas1a, Oas2
and Oas3 were assessed by qRT-PCR. The mRNA expression levels relative to β-actin
mRNA were expressed as 2–ΔCT, (ΔCT = CT（gene of interest）–CT（β-actin）). (B-E) Primary cultures
were pretreated with IFN and infected with A59 and ns2H126R. Virus was titered from the
supernatants at the indicated times (shown in black). Also shown in gray are the titers
from untreated cultures, for panels B-D, the same data from Figure 2.5. The data are
from one representative of two experiments performed in triplicate and are shown as
the means ± the SEM. p <0.05; **, p < 0.01.
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Figure 2.9. Activation of RNase L by other viruses and poly(I:C). (A) BMMs and
astrocytes were infected with A59, ns2H126R, EMCV, LACV and SeV (1 PFU/cell of SeV and
LACV and 0.1 PFU/cell of EMCV). RNA was extracted from infected cells and rRNA
degradation was assessed by Bioanalyzer. The positions of 18S and 28S rRNAs are
indicated. Data shown are taken from three separate chips: 1) BMM RNA; 2) SeV
infected cell RNA; 3) mock, A59, ns2H126R, EMCV, and LACV infected cell RNA. (B)
Astrocyte and neuron cultures were treated with 100 U/ml IFN for 24 h and transfected
with 10 µg/ml pIC with Lipofectamine-2000. Six hours later, RNA was extracted and
rRNA degradation was assessed by Bioanalyzer. Astrocyte and neuron RNA were
analyzed on separate chips. The data are from one representative of two experiments.
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Figure 2.10. Activation of RNase L in isolated brain regions. (A) IN A59 and ns2H126R
infection of WT mice at 5 dpi using 100,000 PFU/mouse (B) IN A59 and ns2H126R infection
of Rnasel-/- mice at 5 dpi using 100,000 PFU/mouse (C) IC A59 and ns2H126R infection of
WT mice at 5 dpi using 100,000 PFU/mouse (D) Basal Oas mRNA expression levels (E)
rRNA degradation assay of WT mice brain regions with A59 and ns2H126R at 100,000
PFU/mouse 5 dpi (F) rRNA degradation assay of Rnasel-/- mice brain regions with A59
and ns2H126R at 100,000 PFU/mouse 5 dpi
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III
CHAPTER THREE
ACTIVATION OF THE OAS–RNASE L PATHWAY BY MURINE CORONAVIRUS IN
MACROPHAGES IS DEPENDENT ON BASAL OAS GENE EXPRESSION AND IS
INDEPENDENT OF VIRUS-INDUCED INTERFERON SECRETION

This chapter is taken from a 2015 published article in the Journal of Virology titled
“Activation of RNase L by murine coronavirus in myeloid cells is dependent on basal Oas
gene expression and independent of virus-induced interferon” by L. Dillon Birdwell, Z.
B. Zalinger, P. W. Wright, R. Elliott, K. M. Rose, R. H. Silverman, and S. R. Weiss
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III.1

ABSTRACT

The oligoadenylate synthetase-ribonuclease L (OAS-RNase L) pathway is a potent
interferon (IFN) induced antiviral activity. Upon sensing double stranded RNA, OAS
produces 2’,5’-oligoadenylates (2-5A), which activate RNase L. Murine coronavirus
(MHV) non-structural protein 2 (ns2), is a 2’,5’-phosphodiesterase (PDE) that cleaves 25A, thereby antagonizing RNase L activation. PDE activity is required for robust
replication in myeloid cells as a mutant of MHV (ns2H126R) encoding an inactive PDE fails
to antagonize RNase L activation and replicates poorly in bone marrow derived
macrophages (BMM) while ns2H126R replicates to high titer in several types of nonmyeloid cells as well as in IFN receptor deficient (Ifnar1-/-) BMM. We reported previously
that myeloid cells express significantly higher basal levels of OAS transcripts than nonmyeloid cells. Here, we investigated the contributions of Oas gene expression, basal IFN
signaling and virus-induced IFN to RNase L activation. Infection with ns2H126R activated
RNase L in Ifih1-/- BMM to a similar extent as in WT BMM despite the lack of IFN
induction in the absence of MDA5 expression. However, ns2H126R failed to induce RNase
L activation in BMM treated with IFNAR1 blocking antibody as well as in Ifnar1-/- BMM,
both expressing low basal levels of Oas genes. Thus, activation of RNase L does not
require virus-induced IFN, but rather correlates with adequate levels of basal Oas gene
expression, maintained by basal IFN signaling. Finally, overexpression of RNase L is not
sufficient to compensate for inadequate basal OAS levels.
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III.2

IMPORTANCE

The oligoadenylate-ribonuclease L (OAS-RNase L) pathway is a potent antiviral activity.
Activation of RNase L during murine coronavirus, MHV, infection of myeloid cells
correlates with high basal Oas gene expression and is independent of virus-induced
interferon secretion. Thus, our data suggest that cells with high basal Oas gene
expression levels can activate RNase L and thereby inhibit virus replication early in
infection upon exposure to viral dsRNA, before the induction of interferon and prior to
transcription of interferon stimulated antiviral genes. These findings challenge the
notion that activation of the OAS/RNase L pathway requires virus to induce type I IFN
which in turn upregulates OAS gene expression as well as to provide dsRNA to activate
OAS. Our data further suggest that myeloid cells may serve as sentinels to restrict viral
replication thus protecting other cell types from infection.
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III.3

INTRODUCTION

The coronavirus mouse hepatitis virus (MHV) strain A59 (A59) causes moderate
hepatitis and mild encephalitis followed by chronic demyelinating disease in susceptible
C57BL/6 (B6) mice (Lavi, Gilden, Wroblewska, Rorke, & Weiss, 1984; Navas-Martin &
Weiss, 2003; Zhao, Rose, Elliott, Van Rooijen, & Weiss, 2011). A59 is cleared from the
liver and central nervous system primarily by the T cell response seven to ten days post
infection (N. W. Marten et al., 2000; N.W. Marten, Stohlman, & Bergmann, 2001).
However, type I interferon (IFN) production, an early innate immune response, is crucial
for early control of MHV infection as mice deficient in type I IFN receptor expression
(Ifnar1-/-) uniformly die by two days after infection (Cervantes-Barragan et al., 2007;
Ireland, Stohlman, Hinton, Atkinson, & Bergmann, 2008; Roth-Cross, Bender, & Weiss,
2008). Interestingly, A59 fails to induce IFNα/β in most cell types, with the notable
exception of myeloid cells (Roth-Cross et al., 2008). Induction of IFNα/β in macrophages
and brain-resident microglia during MHV infection is dependent on sensing of viral
dsRNA by the cytosolic RNA helicase, melanoma differentiation-associated gene 5
(MDA5) encoded by Ifih1 (Kumagai, Takeuchi, & Akira, 2008; Roth-Cross et al., 2008;
Takeuchi & Akira, 2007). IFN induces a large array of interferon-stimulated genes (ISGs),
which include pattern recognition receptors (PRRs), signaling molecules, transcription
factors, and antiviral effectors (Dong & Silverman, 1995; Durbin et al., 2000; Malathi,
Dong, Gale, & Silverman, 2007; Muller et al., 1994; Silverman, 2007b; Zhou et al., 1997).
(Figure 3.1, left side diagrams IFN synthesis and signaling in MHV infected
macrophages). The only other source of type I IFN during A59 infection, primarily IFNα,
is induced through a TLR7-dependent pathway in plasmacytoid dendritic cells (pDC)
(Cervantes-Barragan et al., 2012).
Among the ISGs are several Oas genes encoding proteins that function as nucleic acid
sensors to synthesize 2’,5’-oligoadenylates (2-5A) in response to viral dsRNA in the host
cytosol (Silverman, 2007a). Mice express several OAS proteins that produce 2-5A,
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including OAS1A/G, OAS2, OAS3 as well as OASL2 (Kakuta, Shibata, & Iwakura, 2002;
Mashimo et al., 2003; Silverman & Weiss, 2014). The 2-5A binds to and activates latent
ribonuclease L (RNase L) by inducing conformational changes and subsequent
dimerization (Dong & Silverman, 1995; Silverman, 2007b; Stark, Kerr, Williams,
Silverman, & Schreiber, 1998). RNase L activation leads to restriction of virus replication
through the degradation of host and viral single stranded RNAs, inhibition of protein
synthesis and finally apoptosis (J. C. Castelli et al., 1998; Castelli, Wood, & Youle, 1998;
Zhou et al., 1997). (Figure 3.1, right side diagrams activation of RNase L).Interactions of
viruses with the OAS-RNase L pathway are complex. Many viruses encode proteins that
inhibit this pathway to various extents, underscoring the significance of this system in
restricting viral propagation (Han et al., 2007; Randall & Goodbourn, 2008; Silverman,
2007b; Sorgeloos, Jha, Silverman, & Michiels, 2013; Zhao et al., 2012). Among the most
potent of these inhibitors is the A59 accessory protein, non-structural protein 2 (ns2), a
2’,5’-phosphodiesterase (PDE) that cleaves 2-5A thereby preventing RNase L activation
(Zhao et al., 2012). An A59 mutant (ns2H126R) expressing an inactive PDE (due to an
H126R substitution of a catalytic histidine residue) fails to effectively antagonize RNase
L, and consequently is attenuated for replication in myeloid cells and in the livers of
mice (Zhao et al., 2012).
We have found that RNase L activation is most robust in myeloid lineage cells, where
basal Oas gene expression levels are highest compared with several other types of nonmyeloid primary cells including astrocytes, neurons, and oligodendrocytes, as well as
transformed cell lines (Zhao et al., 2013). Constitutive, low level type I IFN production in
the absence of infection maintains basal levels of expression of ISGs, including OAS
(Sato, Taniguchi, & Tanaka, 2001; Taniguchi & Takaoka, 2001). It has been generally
accepted that RNase L activation requires viral infection to both induce type I IFN
production which in turns upregulates OAS gene expression and to provide dsRNA for
activation of OAS to produce 2-5A (Silverman, 2007b). Thus, unlike most other IFN56

induced activities, which can be stimulated in uninfected cells by paracrine IFN
exposure, RNase L can be activated only in infected cells.
To further elucidate the cell-type dependent determinants of RNase L activation, we
investigated basal Oas mRNA expression, basal IFN signaling, and viral induction of IFN
as three potential contributors. Our data indicate that RNase L activation depends on
relatively high basal mRNA expression levels of Oas genes typical of myeloid cells and
overexpression of RNase L is not sufficient to overcome insufficient levels of OAS.
Furthermore, RNase L activation requires adequate basal IFN signaling to maintain basal
Oas mRNA expression. However, in contrast to the current paradigm, RNase L activation
does not require IFN induction during virus infection of macrophages. These data
suggests that myeloid cells can activate RNase L early during infection and before the
induction of IFN and thereby limit viral spread to other cell types.
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III.4

OBSERVATIONS

III.4.i

Activation of RNase L during ns2H126R infection of dendritic cells correlates with
high basal Oas gene expression

We showed previously that while A59 antagonizes the OAS-RNase L pathway in myeloid
lineage cells, including brain-resident microglia and liver-resident Kupffer cells as well as
bone marrow derived macrophages (BMM) (Roth-Cross et al., 2009; Zhao et al., 2013;
Zhao et al., 2012; Zhao et al., 2011), ns2H126R, a mutant expressing an inactive
phosphodiesterase (PDE) fails to antagonize RNase L and consequently has severely
restricted replication in these cell types. In contrast, replication of ns2H126R in primary
cell types including neurons, astrocytes, and hepatocytes as well as in immortalized cell
lines was as robust as A59 (Zhao et al., 2013; Zhao et al., 2012; Zhao et al., 2011). We
investigated whether other myeloid cells, such as dendritic cells, would behave similarly
to macrophages upon infection. Thus, we compared the replication of A59 and ns2H126R
in BMM and bone marrow derived dendritic cells (BMDC), derived from B6 (WT) mice.
As observed in BMM (Figure 3.2A) (Zhao et al., 2013; Zhao et al., 2012), BMDC (Figure
3.2B) also restricted mutant virus replication by 100 fold at 12 hours (p<0.01) and 1000
fold after 24 hours post infection (p<0.001).
We next compared the basal level of expression of Oas genes in BMDC with those of
BMM and neurons. Using real-time quantitative qRT-PCR, we quantified basal levels of
expression of three Oas genes that encode catalytically active OAS proteins, Oas1a,
Oas2, and Oas3, in WT BMM and WT BMDC cultures in comparison to primary neurons
(Figure 3.2C), the latter shown previously to express minimal basal levels of OAS genes
and to be unable to restrict replication of ns2H126R (Zhao et al., 2013). Oas mRNA
expression levels in neurons, as expected, were under the limit of detection and in
comparison basal mRNA expression levels of Oas1a, Oas2, and Oas3 genes in WT BMM
and WT BMDC were 1000 fold greater than the minimal detectable level (Figure 3.2C).
Levels of OAS1A, OAS2, OAS3, and RNase L were similar in BMM and BMDC culture, as
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assessed by immunoblotting (Figure 3.2D). In order to compare RNase L activation
during A59 and ns2H126R infection, we monitored the state of ribosomal RNA (rRNA)
cleavage in WT BMM and BMDC infected with either ns2H126R or A59. The mutant virus
ns2H126R induced rRNA cleavage at 9 and 12 hours post infection in BMM and BMDC
(Figure 3.2E). In contrast, A59 did not induce rRNA cleavage, similar to mock infected
cells, even at the later time points. Thus, BMDC behaved similarly to BMM in activation
of RNase L and restriction of mutant virus and activation of RNase L correlated with
elevated basal levels of Oas genes (Zhao et al., 2013).
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III.4.ii Overexpression of RNase L does not overcome low basal Oas mRNA expression
to promote RNase L activation by ns2H126R
We investigated whether the level of RNase L expression contributes to the differences
observed between activation of RNase L and ns2H126R replication in myeloid and nonmyeloid cells. Thus, we compared BMM and astrocytes, the latter previously shown to
express low levels of Oas genes (Zhao et al., 2013). We quantified Rnasel protein levels
by Western blot in BMM and astrocytes using cells derived from Rnasel-/- mice as a
negative control. There were no significant differences between protein expression in
BMM and astrocytes (Figure 3.3A).
As RNase L activation is dependent on the production of 2-5A, we investigated whether
overexpression of RNase L might enable the low level of 2-5A produced by cells with low
basal Oas mRNA expression to activate RNase L to degrade rRNA in response to ns2H126R
infection. For this we used a murine 3T3 cell line (3T3/pLZ) that stably overexpresses
human RNase L from a cytomegalovirus (CMV) promoter at a level greater than 100-fold
that of endogenous murine RNase L cells or endogenous human RNase L in A549 cell.
Human RNase L was previously demonstrated to be activated in 3T3/pLZ when exposed
to 2-5A. (Zhou et al., 1998). Indeed, RNase L protein levels are much greater in 3T3/pLZ
cells as compared with A549 (Figure 3.3B). The A549 cell line is derived from human
lung epithelium and expresses sufficient endogenous RNase L to be activated upon viral
infection (Cooper et al., 2015). However, the 3T3/pLZ cells and control 3T3/neo lacking
the human RNase L gene expressed a relatively low level of Oas mRNA similar to that of
the murine L2 cell line (Zhao et al., 2013) (Figure 3.3D). Upon infection of 3T3/pLZ cells
with A59 and ns2H126R, both viruses replicated to high titer as in control 3T3/neo cells
(Figure 3.3D). Furthermore, RNase L was not activated by ns2H126R, as assessed by rRNA
degradation at 9 or 12 hours post infection (Figure 3.3E). Treatment with p(I:C) with or
without prior IFN treatment did activate RNase L in both cell types demonstrating that
RNase L was active when OAS levels are induced. Thus, RNase L overexpression in
3T3/pLZ could not overcome the minimum 2-5A threshold needed to activate RNase L.
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III.4.iii RNase L is activated in the absence of virus-induced interferon in macrophages
While A59 induces type I IFN expression in only a limited number of cell types, primarily
myeloid cells (Roth-Cross et al., 2008; Roth-Cross, Martinez-Sobrido, Scott, GarciaSastre, & Weiss, 2007), the activation of RNase L during infection (with ns2H126R) occurs
only in the same limited cell types (Roth-Cross et al., 2008; Roth-Cross et al., 2007; Zhao
et al., 2013). Thus, we investigated whether virus-induced IFN was necessary to activate
RNase L presumably by further upregulating the already high basal levels of OAS
expression. IFN production during MHV infection of macrophages is dependent on
MDA5 signaling (Roth-Cross et al., 2008). Indeed, using a sensitive bioassay for antiviral
activity (Park et al., 2003) we confirmed that both A59 and ns2H126R infected WT BMM,
secreted detectable antiviral activity at 12 and 24 hours post infection (Zhao et al.,
2013), while infected MDA5 deficient (Ifih1-/-) BMM failed to secrete detectable levels
(Figure 3.4A). We confirmed the presence of IFN in these WT BMM supernatants by
quantifying the level of IFNβ secreted at 12 hours post infection by ELISA. In WT BMM,
MHV infection elicited detectable but low levels (20 to 25 pg/mL) of IFNβ (Figure 3.4B),
while Ifih1-/- BMM cultures did not produce detectable IFNβ. Replication of ns2H126R was
100 fold reduced at 12 hpi and 1000 fold attenuated after 24 hours in Ifih1-/macrophages (Figure 3.4D) compared to A59 in WT BMM (Figure 3.4C) (Zhao et al.,
2012) indicating that ns2H126R replication is restricted in BMM even in the absence of
virus-induced IFN production.
Consistent with the above findings, we observed similar levels of Oas and Rnasel mRNA
in WT and Ifih1-/- BMM (Figure 3.4E). In addition, the protein levels of OAS1A, OAS2,
OAS3, and RNase L were similar between BMM cultures derived from WT or Ifih1-/- mice
(Figure 3.4G). There is some variation in the protein levels among preparations and in
this particular blot, the levels appear to be higher for MDA5 than WT BMM. Also shown
are the levels of OAS protein in cells treated with IFN. Interestingly the levels of OAS
proteins are not much greater than in untreated cells. Furthermore, we compared the
levels of other ISGs in WT and Ifih1-/- BMM and found little difference in their relative
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mRNA expression levels, with the exception of MDA5, which as expected was not
expressed in Ifih1-/- BMM cultures (Figure 3.4F). Finally, RNase L activation was observed
in both genotypes of BMM by 12 hours post infection with ns2H126R while it was also
evident at 9 hours in WT cells. Thus, infection with ns2H126R activated RNase L in the
absence of virus-induced IFN (Figure 3.4H).
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III.4.iv Basal interferon signaling is required for maintenance of adequate Oas mRNA
levels and RNase L activation in macrophages
Basal IFN signaling is necessary to maintain basal expression of ISGs, which enables the
cell to quickly respond to infection by inducing IFN as well as upregulating antiviral ISGs
(Gough, Messina, Clarke, Johnstone, & Levy, 2012). Indeed, we have reported much
higher levels of ISG expression in myeloid cells that are able to induce IFN and activate
RNase L during MHV infection, as compared to other cell types (Zhao et al., 2013; Zhao
et al., 2011). As in the data shown above (Figure 3.4C)(Zhao et al., 2011), ns2H126R was
preferentially restricted compared to A59 in WT BMM starting at 9 hours (p<0.05) and
100 fold decreased from 12 to 24 hours after infection (p<0.01) (Figure 3.5A). However,
replication of ns2H126R was fully recovered in Ifnar1-/- BMM (Figure 3.5B).
We compared the expression of several Oas genes in WT and Ifnar1-/- BMM and found
reduced expression of Oas1a (p<0.01), Oas2 (p<0.001), and Oas3 (p<0.01) mRNAs in
Ifnar1-/- BMM, presumably due to loss of basal IFN signaling, but no significant
difference in Rnasel mRNA expression (Figure 3.5C). Furthermore, we compared the
basal protein expression levels of OAS1A, OAS2, and RNase L in BMM derived from WT
or Ifnar1-/- mice. OAS1A, OAS2 and OAS3 protein was undetectable in cell lysates from
Ifnar1-/- BMM cultures (Figure 3.5D) with or without prior IFN treatment. While OAS
proteins are modestly induced by IFN treatment of WT BMM, RNase L protein
expression is not dependent on IFNAR expression nor is it induced by IFN treatment.
Basal expression levels of other ISG mRNA [including Ifih1 (p<0.05), Ddx58 (p<0.01),
Ifit1, Ifit2, Isg15, and Irf7 (p<0.0001)] were significantly decreased in the absence of
IFNAR1 signaling compared to WT BMM. Irf3 expression level, which is independent of
IFNAR1 signaling (Sato et al., 2000), was similar in WT and Ifnar1-/- BMM. Moreover, Ifnb
expression levels were comparable in both genotypes and near the limit of detection
(Figure 3.5E). Additionally, degradation of rRNA was assessed in lysates from infected
BMM cultures at 9 and 12 hours post infection. In WT BMM cultures, ns2H126R infection
induced rRNA degradation; however, in Ifnar1-/- BMM cultures, RNase L was not
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activated and rRNA degradation was not observed (Figure 3.5F) supporting the notion
that adequate basal levels of OAS gene expression are required for activation of RNase L
upon virus infection.
We hypothesized that the difference in basal ISG expression between macrophages and
astrocytes could be at least in part due to the cell surface expression level of type I
interferon, IFNAR1. Cells with higher IFNAR1 surface expression might promote higher
basal IFN signaling and ISG levels and therefore be more likely to activate RNase L in the
presence of dsRNA early during ns2H126R infection. To assess surface IFNAR1 expression
on BMM, microglia, and astrocytes, BMM and primary astrocyte/microglia cultures were
stained for identifying markers and IFNAR1 and then analyzed by flow cytometry. As
astrocytes displayed a larger range in size as compared to macrophages (data not
shown), we applied a size normalization algorithm to determine density of surface
IFNAR1. Using previously described methods (Knijnenburg et al., 2011) fluorescence
intensity, dependent on both surface IFNAR1 density and cell surface area, was
normalized by cell size to enable comparison of extent of relative IFNAR1 expression
across cell types. Surface density of IFNAR1 was higher in microglia and BMM compared
to astrocytes (Figure 3.5G), perhaps contributing to the higher extent of basal ISGs
detected in myeloid cells.
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III.4.v Modulation of surface IFNAR1 activity regulates basal Oas mRNA expression
and RNase L activation
To complement the infections in Ifnar1-/- BMM and to further explore the relationship
between IFN signaling, basal Oas gene expression and activation of RNase L, we aimed
to modulate IFNAR1 activity on WT BMM such that adequate basal IFN signaling would
be maintained but the cells would not be capable of further upregulating ISGs upon
infection. We used a monoclonal antibody (MAR1-5A3) specific for the IFNAR1 subunit
of the murine IFN receptor that binds to cell surface IFNAR1 and blocks ligand-induced
intracellular receptor signaling and induction of ISGs (Fenner et al., 2006; Lazear, Pinto,
Vogt, Gale, & Diamond, 2011; Pinto et al., 2011; Samuel et al., 2006). Following one
hour of 2 µg/mL antibody pretreatment of WT BMM, there was no increase in Oas1,
Oas2 or Oas3 mRNA expression following infection, and the basal levels of mRNAs in
mock infected cells were the same as in “no mAb” controls (Figure 3.6A-C). Other ISGs,
for example Ifit1, also failed to be induced following infection (data not shown). Under
these conditions, RNase L activity was still activated by infection with ns2H126R at 9 and
12 hours post infection (Figure 3.6G) resulting in restriction of viral replication (Figure
3.6E). Thus, with a one hour pretreatment with 2 µg/mL of antibody, basal mRNA levels
of OAS genes are maintained and BMM retain the ability to restrict MHV and activate
RNase L, in the absence of upregulation of Oas expression levels. However, the use of a
higher dose of antibody (5 µg/mL) recapitulated the phenotype observed in Ifnar1-/BMM in that basal levels of Oas mRNA expression in mock infected mice were
decreased approximately 10 fold (Figure 3.6A-C; compare mock infected, 5 µg/mL mAb
treated to mock infected, no mAb treatment). In addition, Oas mRNA levels were not
induced by infection and activation of RNase L did not occur as assessed by an rRNA
degradation assay (Figure 3.6G) and replication of ns2H126R was no longer restricted
(Figure 3.6F). It is important to note that treatment of cells with an isotype control
antibody had no effect on replication of A59 or ns2H126R and that the replication of
ns2H126R was restricted following treatment with isotype control antibody (Figure 3.6F)
indicating the effects were specific for IFNAR1 (Figures 3.6E&F). Thus, consistent with
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our observations from infection of Ifnar1-/- and Ifih1-/- BMM (Figures 3.4&5) activation of
RNase L correlated with Oas gene basal level of expression and did not require further
upregulation during infection.
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Figure 3.1. OAS-RNase L pathway. Interferon induction and signaling (left side) (1) Viral
dsRNA is produced during virus replication (2) dsRNA is sensed by PRRs such as MDA5,
initiating a signaling pathway leading to (3) transcription, translation and secretion of
IFNα/β. (4) Autocrine and paracrine IFN signaling through the interferon receptor
(IFNAR1) (5,6) stimulates the expression of ISGs. RNase L activation (right side) (7) OAS
sense viral dsRNA and synthesize 2-5A (8) 2-5A binds to RNase L inducing its
dimerization and subsequent activation. (9) RNase L degrades RNA.
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Figure 3.2. Activation of RNase L by ns2H126R during infection of BMM and BMDC
cultures. (A) BMM and (B) BMDC cultures were infected with A59 or ns2H126R (1
PFU/cell) and at the times indicated, the virus titer was determined by plaque assay
from the supernatant. The data are pooled from two independent experiments carried
out in triplicate and shown as the means ± SEM. *, P< 0.05; **, P < 0.01; ***, P < 0.001.
(C) RNAs was extracted from infected BMM, BMDC and neuron cultures and
Oas1a, Oas2, and Oas3 mRNA expression was quantified by qRT-PCR. Expression levels
of mRNA relative to β-actin mRNA are expressed as 2−ΔCT, where ∆CT = (CT, Target Gene - CT, βactin). The dashed line designates the lower limit of detection. These data are from one
representative experiment of two, each performed in triplicate. (D) Protein lysates from
BMM and BMDC were electrophoresed in acrylamide gels and then probed with
antibodies against OAS1A, OAS2, OAS3, RNase L (mAb), and GAPDH. (E) RNA was
extracted from infected BMM and BMDC cultures at 9 and 12 hours post infection as
well as cultures 12 hours post mock infection and rRNA degradation was assessed with
an Agilent 2100 Bioanalyzer. The positions of 28S and 18S rRNA are indicated.
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Figure 3.3. Overexpression of RNase L is not sufficient to overcome low OAS levels to
promote RNase L degradation. (A) Proteins were extracted from WT and Rnasel-/- BMM
and astrocytes, electrophoresed in polyacrylamide gels and probed by Western blot
with antibodies directed against RNase L (rabbit polyclonal) and β-tubulin. BMM and
astrocyte cell lysates were electrophoresed on the same gel and blotted at the same
time and intervening lanes were removed and replaced by space between samples.
(B) Proteins were extracted from human A549 and murine 3T3/pLZ cells,
electrophoresed in polyacrylamide gels and probed by Western blot with antibodies
directed against human RNase L and human β-tubulin. (C) RNA was extracted from L2,
3T3/pLZ, 3T3/neo, and BMM cultures and basal expression levels of Oas mRNAs were
quantified by qRT-PCR. In A and C, mRNA expression levels relative to β-actin mRNA are
expressed as 2−ΔCT, where ∆CT = (CT, Target Gene - CT, β-actin). Data are from one representative
experiment of two each performed in triplicate except for 3T3/neo data. The dashed
line designates the lower limit of detection. (D) 3T3/pLZ and 3T3/neo cells were infected
with A59 or ns2H126R (1 PFU/cell) and at the times indicated, the virus titer was
determined by plaque assay from the supernatant. Data are pooled from two
independent experiments (3T3/pLZ) or from one experiment (3T3/neo) each performed
in triplicate. (E) Cells were pretreated with 100 units/mL of IFNα for 4 hours and/or
transfected with 1 ug/mL p(I:C) or infected as in panel E. RNA was extracted at 9 and 12
hours post transfection or post infection and rRNA degradation was assessed with an
Agilent 2100 Bioanalyzer. The 18S and 28S rRNAs are indicated.
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Figure 3.4. Infection of Ifih1-/- macrophages with A59 and ns2H126R. (A) WT or Ifih1-/BMM cultures were either mock infected or infected with A59 or ns2H126R (1 PFU/cell).
At 12 hours post infection, supernatants were treated with UV light to inactivate virus
and incubated with L2 mouse fibroblasts for 24 h, followed by infection with NDV-GFP (1
PFU/cell). As a positive control, L2 cells were treated with IFNα for 24 h and then
infected with NDV-GFP. At 12 or 24 hours post infection, cells were fixed and examined
for enhanced-GFP expression by microscopy. (B) Supernatants taken at 12 hours post
infection from the same mock infected or A59 and ns2H126R infected WT and Ifih1-/- BMM
cultures were analyzed by ELISA for mouse IFNβ by VeriKine kit. Limit of detection is
indicated by dashed line. Data are from one representative experiment of two. (C) WT
BMM and (D) Ifih1-/- BMM cultures were infected with A59 and ns2H126R (1 PFU/cell) and
at the times indicated, the virus titer was determined by plaque assay from the
supernatant. Data are pooled from two independent experiments performed in
triplicate and shown as the means ± SEM. *, P < 0.05; **, P < 0.01; ***, P< 0.001. (E and
F) mRNA expression levels relative to β-actin mRNA are expressed as 2−ΔCT, where ∆CT =
(CT, Target Gene - CT, β-actin). Dashed line designates the lower limit of detection. Data shown
are pooled from two independent experiments each performed in triplicate and shown
as the means ± SEM. *, P < 0.05; **, P < 0.01; ***, P< 0.001. (G) Proteins were extracted
from WT and Ifih1-/- BMM and probed by Western blot with antibodies directed against
OAS1A, OAS2, OAS3, RNase L (mAb), and GAPDH. (H) RNA was extracted from infected
WT and Ifih1-/- BMM cultures at 9 and 12 hours post infection as well as cultures 12
hours post mock infection and rRNA degradation was assessed with an Agilent 2100
Bioanalyzer. The 28S and 18S rRNAs are indicated.
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Figure 3.5. RNase L is not activated during infection of Ifnar1-/- macrophages. (A) WT
and (B) Ifnar1-/- BMM cultures were infected with A59 or ns2H126R (1 PFU/cell) and at
times indicated virus titered by plaque assay from the supernatant. Data are pooled
from two independent experiments performed in triplicate and shown as the means ±
SEM. *, P < 0.05; **, P < 0.01; ***, P< 0.001. (C) RNA was extracted from uninfected WT
and Ifnar1-/- BMM cultures and Oas1a, Oas2, Oas3, and Rnasel mRNA were quantified
by qRT-PCR. mRNA expression levels relative to β-actin mRNA are expressed as 2−ΔCT,
where ∆CT = (CT, Target Gene - CT, β-actin). The dashed line designates the lower limit of
detection. (D) Protein was extracted from WT and Ifnar1-/- BMM cultures,
electrophoresed in polyacrylamide gels and probed with antibodies directed against
OAS1A, OAS2, OAS3, RNase L (mAb), and GAPDH. (E) RNA was extracted from
uninfected WT and Ifnar1-/- BMM cultures and ISG mRNA were quantified by qRT-PCR.
Expression levels of mRNA relative to β-actin mRNA are expressed as 2−ΔCT, where ∆CT =
(CT, Target Gene - CT, β-actin). The dashed line designates the lower limit of detection Data are
from one representative experiment of two, each performed with triplicate and shown
as the means ± SEM. *, P < 0.05; **, P < 0.01; ***, P< 0.001; ****, P < 0.0001. (F) RNA
was extracted from BMM cultures at 9 and 12 hours post infection as well as cultures 12
hours post mock infection and rRNA degradation was assessed with an Agilent 2100
Bioanalyzer. The 28S and 18S rRNAs are indicated. (G) Astrocytes and microglia, from
mixed glial cultures, and macrophages, from bone marrow derived cultures, were
stained with cell type specific antibodies, as well as for IFNAR1, analyzed by flow
cytometry with an LSR II (Becton Dickinson), and the resulting data were analyzed using
FlowJo Software (Treestar). Astrocytes (GFAP+CD11b-F4/80-), microglia (GFAPCD11b+F4/80+), and macrophages (GFAP-CD11b+F4/80+) were assessed for surface
expression of IFNAR1. Data are from one representative experiment of two, each
performed with triplicate cultures of each cell type.
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Figure 3.6. Activation of RNase L activity in BMM treated with IFNAR1 blocking MAR15A3 mAb. WT BMM were treated with 2 µg/mL or 5 µg/mL MAR1-5A3 IFNAR1 blocking
mAb or no mAb or isotype control Ab (panels E and F only) for 1 hour before infection or
mock infection with A59 or ns2H126R (1 PFU/cell). RNA was extracted from cells at 0 time
post mock infection and 12 hours post virus infection. Expression levels of (A) Oas1a, (B)
Oas2, and (C) Oas3 mRNA were quantified by qRT-PCR. Levels of mRNA expression
relative to β-actin mRNA are expressed as 2−ΔCT, where ∆CT = (CT, Target Gene - CT,β-actin). The
dashed line designates the lower limit of detection. These data are pooled from two
independent experiments, each performed in triplicate and are shown as the means ±
SEM. Values for mock infected, 5 µg/mL mAb treated are significantly different from
mock infected, 0 mAb or 2 µg/mL mAb treated, *, P <0.05; Supernatants from A59 or
ns2H126R infected BMM cultures pretreated with (D) no mAb, (E) 2 µg/mL IFNAR1
blocking mAb (solid line) or istoype control Ab (dotted line), and (F) 5 µg/mL of IFNAR1
blocking mAb (solid line) or istotype control Ab (dotted line) were titered for virus by
plaque assay. Data are pooled from three independent experiments using MAR1-5A3 or
one experiment using isotype control antibody, each performed in triplicate and are
shown as the means ± SEM. *, P < 0.05; **, P < 0.01. (G) RNA was extracted at 9 and 12
hours post infection from BMM cultures that had been pretreated with mAb as
indicated, and rRNA degradation was assessed with a Bioanalyzer. 28S and 18S rRNAs
are indicated. RNA from mock infected cultures appeared similar to that from A59
infected cells (not shown) as in Figures 3.2E, 3.3F, 3.4H, and 3.5F.
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IV
CHAPTER FOUR
CONCLUSIONS AND GENERAL DISCUSSION
Previous studies from our lab (Zhao et al., 2012; Zhao, Rose, Elliott, Van Rooijen, &
Weiss, 2011b) and others (Daffis, Samuel, Keller, Gale, & Diamond, 2007; Ida-Hosonuma
et al., 2005; Ida-Hosonuma et al., 2003) have shown that basal as well as virus- and/or
IFN-induced levels of ISG expression are important determinants of permissiveness to
viral infection and the resulting cellular and organ tropism. We have reported previously
that the basal expression levels of mRNAs encoding ISG proteins, including MDA5,
STAT1 and other molecules that crucial for recognizing viral invasion and producing an
antiviral environment, were greater in the liver than in the CNS and also higher in
myeloid cells than in other cell types (Zhao et al., 2012; Zhao et al., 2011b; H. Zhou,
Zhao, & Perlman, 2010). Similarly, microglia isolated from naïve mice or mice infected
with an attenuated neurotropic strain of MHV expressed higher basal and induced levels
of ISG mRNA than did oligodendrocytes (Kapil, Butchi, Stohlman, & Bergmann, 2012).
We show here that the expression levels of Oas mRNAs follow similar patterns. The
basal mRNA expression levels of the active Oas species Oas1a, Oas2, and Oas3 are 100
to 1000-fold higher in the liver than in the brain, suggesting that the low level of OAS
expression in the brain precludes activation of the OAS-RNase L pathway and allows the
replication of ns2H126R. Similarly among cell types examined, myeloid cells express the
highest basal levels of Oas and are the only cell types thus far tested in which MHV
needs an enzymatically active ns2 to ensure efficient replication. Bone marrow dendritic
cells, also of myeloid lineage, preferentially restrict ns2H126R (Figure 3.2B).
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Compared to myeloid-derived cell types, after infection with A59 or ns2H126R, neurons
and oligodendrocytes showed little increase in Oas mRNA expression, while the Oas
expression levels in astrocytes were significantly upregulated, although not to the levels
in myeloid cells (Figure 2.6C). Virus replication in oligodendrocytes and astrocytes is
robust, with titers similar to those produced in microglia or in L2 cell lines. Indeed, A59
causes cytopathic effect (syncytia) in primary microglia and astrocyte cultures. While
virus remains more cell-associated in neurons, it appears to spread rapidly cell-to-cell in
infected primary neuronal cultures (Bender, Phillips, Scott, & Weiss, 2010). Thus, the
lack of activation of RNase L is not due to a low percentage of infected cells.
Pretreatment of these cultures with IFNα to induce the expression of Oas mRNAs as
might occur in vivo (Figure 2.7B-E) did not produce activation of RNase L in any nonmyeloid cell type (data not shown) including hepatocytes, and consequently all
permitted ns2H126R to replicate similarly to A59. Interestingly, other interferonstimulated antiviral activities were clearly effective in all cell types, as the viral titers
were lower in pretreated cultures by approximately 100-fold for astrocytes and
oligodendrocytes and to a lesser extent for neurons as compared to about 1000-fold in
microglia. Similarly, West Nile virus replication was significantly less restricted by IFN
pretreatment of primary neuronal cultures as compared with macrophages and this
correlated with relatively low levels of ISG expression in neuronal cultures (Daffis et al.,
2007; Daffis, Suthar, Gale, & Diamond, 2009).
In order to investigate whether introduction of MHV through a less artificial route of
infection would induce a protective RNase L response, we inoculated virus intranasally.
Olfactory bulb neurons may be specialized to control viruses, as they are most exposed
to environmental factors. In addition, they continue to replicate in vivo in adult mice
(Cowan & Roskams, 2002) and thus may tolerate higher levels of ISG expression. Indeed,
ISG induction has been reported in the olfactory bulb, most likely in neurons, in
response to vesicular stomatitis virus (VSV) (Detje et al., 2009; Lang et al., 2010).
Similarly, VSV infection was restricted by the IFN-stimulated gene product of IFIT2
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following intranasal but not intracranial inoculation, suggesting that IFN produced
during infection of olfactory bulb neurons induced IFIT2 expression throughout the
brain (Fensterl et al., 2012). However, when inoculated via the intranasal route, ns2H126R
was not preferentially restricted relative to A59 (Figure 2.2), implying that the cells of
the nasal epithelium and the olfactory neurons were not better able to prevent viral
invasion. Consistent with these data, we found no significant differences in the basal
levels of Oas mRNA levels among RNA samples extracted from the olfactory bulbs and
from other regions of the brain (data not shown). Interestingly, however, it has recently
been reported that cultured granular neurons of the cerebellum express higher basal
levels of ISG mRNA, as compared with cortical neurons and are consequently more
restrictive of infection with several viruses including MHV-A59 (Cho, 2013).
The correlation of RNase L activation with high basal Oas gene expression suggests that
production of 2-5A is the limiting step in activation. While Oas expression levels were
quite variable among murine cell types, we found similar levels of RNase L expression in
murine BMM and astrocytes (Figure 3.3A&B), cell types expressing high and low levels
of Oas genes, respectively. Furthermore, basal levels of Rnasel transcripts and proteins
were not dependent on IFNAR signaling in BMM (Figure 3.5C). However, to investigate
whether a high level of RNase L could overcome the requirement for high OAS levels to
produce 2-5A, we carried out infections in murine 3T3/pLZ cells, which overexpress
RNase L to a level about 100 fold greater than endogenous RNase L (A. Zhou et al.,
1998). RNase L was not activated in this cell type by either A59 or ns2H126R, indicating
that OAS activity is the limiting step for RNase L activation as extremely high levels of
RNase L were not sufficient to overcome insufficient levels of Oas gene expression
(Figure 3.3).
We present further evidence that in myeloid cells, RNase L can be activated in the
absence of MDA5, the recognition receptor necessary for the induction of IFN during
MHV infection (Roth-Cross, Bender, & Weiss, 2008), as long as Oas gene expression
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remains at a minimum threshold level maintained by basal IFN signaling. The reduced
levels of Oas gene expression in BMM derived from Ifnar1-/- mice or B6 mice treated
with 5 µg/mL IFNAR1 blocking antibody preclude the activation of RNase L during
ns2H126R infection. These data suggest that the basal level of Oas expressed in BMM
derived from WT B6 or Ifih1-/- mice is adequate to produce enough 2-5A to activate
RNase L in the absence of virus-induced IFN.
Differences in anatomical structure and cellular composition of the liver and brain might
account for the differences observed with MHV-A59 and ns2H126R infection. The liver is a
detoxifying organ that helps filter blood from numerous pathogens and debris through
its vast network of small blood vessels or sinusoids. Ongoing immune responses from
constant antigen exposure may induce type I IFN expression and maintain higher basal
levels of ISG expression in the liver than in the brain (Zhao, 2011; Cho, 2013). The liver
parenchyma is composed mainly of hepatocytes, while non-parenchymal KC, the
resident macrophages of the liver, and liver sinusoidal endothelial cells (LSEC) are
located within the sinusoids (Crispe, 2009). LSEC line the sinusoids of the liver and are
some of the first cells to be exposed to pathogens entering the liver from the
bloodstream. We have proposed that KC serve as a gatekeeper to restrict entrance from
the sinusoids into the liver parenchyma to infect hepatocytes (Zhao, 2011; Zhou, 2010;
Cho, 2013). We suggest that upon infection of KC, the IFN response, including
importantly the OAS-RNase L pathway, creates an antiviral state restricting infection and
limiting spread of virus to the parenchymal hepatocytes, consequently preventing
hepatitis. This hypothesis is supported by the following observations. Infection of mice
with CD11b+ cell type specific ablation of type I interferon receptor expression (Ifnar1-/-)
demonstrated that IFN signaling in macrophages is crucial for control of hepatitis
induced by MHV (Cervantes-Barragan et al., 2009) as well as by lymphocytic
choriomeningitis virus (Lang et al., 2010). Expression of an active ns2 phosphodiesterase
by A59 facilitates viral replication in macrophages by antagonizing the OAS-RNase L
pathway, thus downregulating the IFN response; this promotes replication in the liver
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parenchyma, leading to hepatitis (Zhao et al., 2011b). Depletion of macrophages
promotes replication of ns2H126R and the subsequent development of liver pathology in
B6 mice (Zhao et al., 2011b), demonstrating that replication in KC is not required for the
induction of hepatitis, but rather that KC protect the host from viral infection. In
addition, KC have highest basal and IFN-induced levels of OAS among liver cell types
(Asada-Kubota et al., 1998). In fact, LSEC are able to restrict the ns2H126R, activate RNase
L, and have high basal Oas mRNA expression levels.
In comparison to the liver, the dichotomous needs for pathogen elimination and
protection from cellular damage make the mammalian CNS a partially protected
environmental niche that is a prime target for viral infections. The concept of the CNS as
an immune-privileged organ has many to believe that it is not an active immunological
organ, guarded from its surroundings by the blood-brain barrier (BBB). However, the
CNS is a highly immunologically active organ, with complex immune responses mostly
based on innate immune processes. In cases of infections, traumas, and pathological
conditions, the CNS encounters many viral PAMPS that can activate PRRs to elicit
antiviral mechanisms. The role for these receptors in the CNS has been mostly studied in
microglia, but astrocytes, oligodendrocytes, endothelial cells, and even neurons express
functional levels of some of these receptors (Hanamsagar et al., 2012). Microglia are
distinct from the monocyte lineage of cells and other tissue-specific macrophages such
as KC in the liver, for which maintenance is dependent upon the recruitment of bone
marrow-derived cells (BMDCs) from the circulation (Klein et al., 2007). In the CNS, BMDC
recruitment does not occur during normal physiology (Lampron et al., 2012). When it
comes to its defense, CNS integrity is guarded exclusively through an innate immune
system with an adaptive immunity only present in specific conditions (Rivest, 2009).
These features make the CNS immune response much different from the liver and other
peripheral organs upon infections.
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Therefore, this means a complex immune reaction is engaged in the CNS in response to
mechanical or ischemic traumas, the accumulation of toxic proteins, or bacterial or viral
infections. A59 infects all major CNS cell types in vivo (Bender et al., 2010; Miura et al.,
2008) as well as in vitro (Figure 2.5A-E). Intracranial infection provides immediate access
to all cell types. Numerous cell types act to maintain CNS integrity and function,
separated into three main groups: neurons, the glia, and endothelial cells. Neurons, glial
cells, and endothelial cells exist in close proximity of each other, forming the
neurovascular unit (NVU), a coherent view of the CNS as a whole instead of a blend of
compartmentalized cell types (Zlokovic, 2008).
Neurons, the most abundant cell type in the murine brain, generally express low levels
of ISG mRNA and minimal basal levels of Oas mRNA, allowing for robust virus
replication. Astrocytes and oligodendrocytes are similarly susceptible to infection.
However, tissue-resident macrophages called microglia, much like KC in the liver or
histiocytes in connective tissues, are the only cells in the CNS that are of hematopoietic
origin (Soulet and Rivest, 2008b). Fate-mapping analysis has demonstrated that
hematopoietic precursors from the yolk sac populate the CNS before the eighth
embryonic day in mice (Ginhoux et al., 2010). Once present, microglia are capable of
self-renewal and do not require replenishment from circulating monocytic precursors
(Ajami et al., 2007). Microglia also restrict ns2H126R replication (Figure 2.5D), albeit less
so than BMMs (K. M. Rose, Elliott, Martinez-Sobrido, Garcia-Sastre, & Weiss, 2010;
Kristine M. Rose & Weiss, 2009; Roth-Cross, Martinez-Sobrido, Scott, Garcia-Sastre, &
Weiss, 2007) and would be expected to limit replication in the brain in vivo. We suggest
that microglia are not able to significantly restrict ns2H126R in the CNS in part because
they represent a minority of infected cells (Phillips, Chua, Rall, & Weiss, 2002). In
addition, by the time microglia and infiltrating macrophages have secreted IFN, which is
late during A59 infection (K. M. Rose et al., 2010; Kristine M. Rose & Weiss, 2009; RothCross et al., 2007), it may be too late to induce OAS-RNase L in other parenchymal cell
types already infected by virus. Furthermore, our in vitro data suggest that IFN
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pretreatment of neurons, astrocytes, and oligodendrocytes also fails to promote an
effective RNase L response in MHV infected cells. In this case, IFN pretreatment leads to
restriction of virus replication for both viruses and not just preferentially with ns2H126R.
This suggests that in different cell types, different pathways and ISGs are important for
restriction. Our data however do not rule out the possibility that a combination of IFN
exposure and infection may trigger RNase L activity in the CNS in vivo. Indeed,
expression of Oas was reported for neurons in brains that had been injected with IFNα
(Asada-Kubota et al., 1997). Consistent with our results, an attenuated MHV-JHM
isolate, with tropism restricted to oligodendrocytes, replicated to similar titers in the
CNS of Rnasel-/- and B6 mice; however, increased foci of infected microglia were
observed in the gray matter in Rnasel-/- mice, implying OAS-RNase L did provide some
protection against viral infection of microglia in that model (Ireland et al., 2009).
Indeed, responses in this compartment must be tightly regulates as the CNS is
composed predominantly of non-renewable cells such as neurons. Thus, unregulated
immune responses could be irreparably destructive to the CNS. High levels of IFNα can
be pathogenic in the CNS, as illustrated by individuals with Aicardi-Goutières, who
produce high levels of IFNα in their cerebral spinal fluid and exhibit symptoms of
chronic encephalitis (Paul et al., 2007; Stephenson, 2008). Unregulated RNase L
mediated degradation has been reported to promote apoptosis potentially damaging to
non-renewable cells (Castelli et al., 1998). The failure to respond to ns2H126R infection by
activation of the OAS-RNase L pathway in neurons, astrocytes, and oligodendrocytes
may reflect the relatively low basal levels of ISG expression that may limit the damaging
effects of excessive IFN signaling (Zhao, 2011; Cho, 2013). Excessive IFN has pathological
effects, contributing to several autoimmune diseases and promoting cancer (de Visser,
2006; Gough, 2012; Trinchieri, 2010).
Given the protective and harmful roles of IFN, it is is vital for control of early MHV
infection in vivo (Cervantes-Barragan et al., 2007; Ireland, Stohlman, Hinton, Atkinson, &
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Bergmann, 2008; Roth-Cross et al., 2008). However, MHV and other coronaviruses, such
as SARS-CoV and MERS-CoV are poor inducers of IFN as they actively inhibit a robust
type I IFN response in infected cells (Roth-Cross, 2007; Spiegel, 2005; Versteeg, 2007;
Chan, 2013; Kindler, 2013; Zielecki, 2013). In the case of MHV, IFN is not detected during
infection of cell lines nor in several types of primary cells in vitro, including the main
types of cells infected in the brain (neurons, astrocytes, and oligodendrocytes) and liver
(hepatocytes) parenchymal cells. However, MHV does induce IFN in macrophages and
microglia (Roth-Cross et al., 2008) as well as pDCs in vivo (Cervantes-Barragan, 2012)
and in myeloid cells in vitro (Roth-Cross et al., 2008). These are the same types of cells
expressing high levels of basal Oas genes and which activate RNase L in response to
ns2H126R, probably as a consequence of the high expression levels of ISGs including
MDA5 and the transcription factors necessary for IFN induction (Chen, 2013; Zhao,
2011). Thus, in vivo, low Oas gene expressing cells may be induced by paracrine IFN to
increase OAS levels enabling viral activation of RNase L. Indeed, in previous experiments
reported by our lab, pretreatment of astrocyte or neurons with IFN did increase the
levels of Oas gene expression (Zhao, 2013). However, IFN pretreatment also resulted in
decreased titers of both A59 and ns2H126R and the absence of activation of RNase L in
those experiments was suggested to be a consequence of reduced ability of both A59
and ns2H126R to replicate and produce dsRNA following IFN pretreatment (Zhao, 2013).
Data here suggest IFN treatment induces many antiviral ISGs some of which inhibit viral
replication without the activation of RNase L. Taken together our data indicate high
basal Oas levels are both necessary and sufficient for the activation of RNase L by MHV
lacking a functional viral PDE.
Type I IFNs are produced constitutively in low quantities–barely detectable at the mRNA
and protein levels in some cell types, such as BMM cultures (Figure 3.5E, data not
shown) and undetectable in most other cell types we have tested (data not shown).
However, this low level of constitutive IFN is believed to have many important effects on
the host. In a healthy organism, ever-present low amounts of IFNβ maintain appropriate
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expression of IFN-inducible signaling intermediaries, including the transcription factors
STAT1, STAT2, IRF5, IRF7, and IRF9. Most cell types are competent to mount type I IFNdependent responses. Immune cells can respond rapidly to low levels of type I IFNs, a
capacity maintained under homeostatic conditions by an positive autocrine loop
whereby small amounts of IFNβ maintain high basal expression levels of Stat1 and Irf9
which are themselves ISGs (Gough, 2012). Basal IFNβ expression and attendant tonic
IFNAR signaling equips immune cells to rapidly mobilize effective antimicrobial
programs. Appropriate expression allows a balance between STAT1 or ISGF3 signaling
and signaling through other STAT proteins (e.g., STAT4). Diminished constitutive IFNβ
secretion results in decreased expression of ISGF3 subunit proteins, altering the balance
of signaling (e.g., between ISGF3 and STAT4) and culminating in susceptibility to
infection and cancer, inefficient hematopoietic stem cell (HSC) mobilization, and
increased bone resorption. Constitutive IFN signaling promotes rapid and efficient
responses to microbial invasion as evidenced by the extreme sensitivity of Ifnar1-/- mice
to many viruses, including MHV (de Visser, Eichten, & Coussens, 2006; Gough, Messina,
Clarke, Johnstone, & Levy, 2012; Trinchieri, 2010). Recent work suggests that basal IFNβ
production under homeostatic conditions is driven in part by the commensal microbial
flora, which thus can systemically calibrate type I IFN responses (Abt, 2012; Ganal, 2012;
Kawashima, 2013).
Somewhat paradoxically, loss of constitutive IFNβ or loss of IFN responsiveness (e.g., as
observed in Ifnar1-/-animals) attenuates cellular responses not only to type I IFNs but
also to unrelated cytokines, such as IFNγ and IL-6 (Takaoka et al., 2000; Mitani et al.,
2001; Der et al., 1998; Weihua et al., 2000). While the transcriptional regulation of IFNβ
mRNA expression in the context of viral infection is extensively characterized, less is
known regarding the transcriptional regulation of constitutive IFNβ. For virus-induced
IFNβ expression, IRF3 and IRF7 appear to be essential (Hata et al., 2001 and Sato et al.,
2000). The binding of each of these components in the correct orientation and location
results in activation of the IFNβ promoter in response to viral infection. The most
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notable distinction from acutely induced IFN expression is a switch from dependency on
IRF3 and IRF7 to c-Jun and NF-κB components. Threshold expression of IFNβ in
unstimulated cells is governed by IRF2 and p50 homodimers, both of which are
constitutively expressed and bind the IFNβ promoter as repressors (Gough, 2012; Cheng
et al., 2011, Senger et al., 2000, Thanos and Maniatis, 1995 and Harada et al., 1989).
IRF2-deficient cells have heightened expression of IFNα and IFNβ and IFN target genes.
Irf2-/- mice develop a psoriasis-like skin disease that is ameliorated by removing IFN
signaling, such as ablation of Ifnar1 (Arakura et al., 2007 and Honda et al., 2003).
Animals with p50 deficiency are developmentally normal with no signs of the skin
disease caused by IRF2 loss, suggesting a lesser role for p50 as a repressor of
constitutive IFNβ (Sha et al., 1995). These reports document that the IFNβ promoter is
occupied by both transcription activators (c-Jun and RelA) and suppressors (IRF2 and
p50 homodimers), the balance of which maintain tight control of constitutive IFNβ in
the absence of overt stimulation. IRF2 might play a significant role in preventing the
detrimental cellular effects in the brain during infection. Indeed, levels of Irf2 mRNA
expression is significantly higher in astrocytes than in BMM. This suggests that
astrocytes are transcriptionally repressed and do not respond to IFN as efficiently as
BMM respond.
The aforementioned methods are not the only mechanisms that suppress type I IFNmediated responses, including downregulation of cell surface IFNAR expression.
Internalization of IFNAR is induced by various heterologous pathways to limit cellular
IFN responsiveness (Fuchs, 2013; de Weerd, 2012). Viruses can induce IFNAR
degradation to evade type I IFN-mediated antiviral responses (Fuchs, 2013; Liu, 2009).
Encephalitic flaviviruses, tick-borne encephalitis virus, and West Nile virus antagonize
IFN signaling by downregulating IFNAR1 surface expression thus reducing IFNβstimulated antiviral gene induction and compromising host control of infection (Lubick
et al., 2015). Interestingly, in a reovirus model of myocarditis, surface expression levels
of IFNAR as well as basal ISG levels were higher in cardiac fibroblasts as compared with
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cardiac myocytes. It was suggested that upon exposure to IFN, cardiac fibroblasts could
quickly develop an antiviral state and thereby avoid serving as a site of replication and
spread to the non-renewable cardiac myocytes (Zurney, Howard, & Sherry, 2007).
Similarly, our data suggest that astrocytes have relatively lower IFNAR1 surface
expression compared to microglia in the brain or BMM (Figure 3.5G), which could
contribute to the lower level of basal ISG expression. MHV might induce the degradation
of the IFNAR receptor on the surface of non-myeloid cells to down play the pathological
effects of IFN signaling in the CNS.
In fact, recent work has revealed that even in populations of nearly identical cells, not all
cells that are infected by a virus or exposed to microbial products produce type I IFNs
and express ISGs. The stochastic nature of ISG expression seems to be related to
bimodal induction of STAT2 and IRF7, which can drive high amounts of ISG transcription
in a particular subset of cells, whereas other cells express much lower amounts of ISG
transcripts. The biological purpose of stochasticity is unclear, but some evidence
suggests that it generates cells that are 'mass IFN producers' (Hwang, 2013; Zhao et al.,
2012; Shalek, 2013). These mass IFN producers help combat infection but might be
more susceptible to cell death, while 'low IFN producers' are preserved in order to
maintain the viability of tissues. Microglia might be mass IFN produces and responders
that are easily sacrificed to maintain and ensure CNS integrity.
Futhermore, in macrophages, suppressor of cytokine signaling 3 (SOCS3), a gene that
encodes a member of the STAT-induced STAT inhibitor (SSI), which is cytokine-inducible
negative regulators of cytokine signaling. SOCS3 is not as highly expressed at the mRNA
level as compared to non-myeloid cells. Type I IFN induces SOCS3 as part of a negative
feedback loop to limit the extent and duration of type I IFN response (Yoshimura, 2007;
Sarasin-Filipowicz, 2009). SOCS proteins compete with STATs for binding to IFNAR and
suppress JAK activity, whereas USP18 displaces JAK1 from IFNAR2. These inhibitory
proteins are also induced by various cytokines that activate JAK–STAT signaling.
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Potentially, non-myeloid cells have less SOCS3 as an attempt to spare themselves the
negative effects of rampant IFN signaling. Conversely, MHV might use this negative
regulator to escape from type I IFN-mediated antimicrobial action.
Additionally, a recent report identified DNA regulatory elements for the transcription
factor forkhead box protein O3 (FOXO3) in several ISG promoters, including IRF7. FOXO3
proposed functions are to repress basal type I IFN responses and shut down the type I
IFN response during the resolution phase of an infection (Litvak, 2012). Relatively little is
known about the repression of ISG expression, and the characterization of additional
repressors represents an important area for future study, especially for cell types of the
brain during viral infection.
In addition to a cell limiting excessive IFN signaling, RNase L must be managed in a way
that will not be detrimental to the host. RNA cleavage products stimulate
inflammasome activation by binding to DExD/H helicase, DHX33 (Chakrabarti, 2015).
Activation of RNase L induces apoptosis involving activity of caspase 3 (Li, 2004) in some
cell types, which correlated with basal levels of OAS and RNase L (Banerjee, 2014). Also,
activation of RNase L induces autophagy involving the activities of JNK and PKR
(Siddiqui, 2012). Phosphorylation of Bcl2 by JNK disrupts complexes with Beclin-1 and
promotes complex formation with Vps34, which is required for autophagosome
formation. RNase L-cleaved RNAs regulate the switch from autophagy to apoptosis that
can determine fate of cells during viral infections. The role of RNase L in the crosstalk
between these pathways is still being explored (Siddiqui, 2015).
One possible explanation for the lack of activation of the OAS-RNase L pathway in nonmyeloid cells despite the induction of other antiviral effectors is the requirement for
viral dsRNA to be accessible to induce the synthesis of 2-5A by OAS. Indeed, the lack of
induction of type I IFN response in non-myeloid primary cell types (Figure 2.7B) as well
as in several transformed cell lines during MHV infection provide further evidence that
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viral RNA may not be accessible for detection by MDA5 in non-myeloid cells (Roth-Cross
et al., 2007; Versteeg, Bredenbeek, van den Worm, & Spaan, 2007; H. Zhou & Perlman,
2007). It has been speculated that MHV (Versteeg et al., 2007; H. Zhou & Perlman,
2007), as well as other viruses such as tick-born encephalitis virus (Overby, Popov,
Niedrig, & Weber, 2010), induces a rearrangement of intracellular membranes that
could potentially create a compartment that would protect viral dsRNA from detection
by cytoplasmic sensors (Hagemeijer, Vonk, Monastyrska, Rottier, & de Haan, 2012;
Knoops et al., 2010; Prentice, McAuliffe, Lu, Subbarao, & Denison, 2004; van den Worm
et al., 2011; van Hemert et al., 2008). However, to our knowledge no studies of MHVinduced membrane rearrangement or localization of viral transcription complexes and
dsRNA have been carried out in myeloid cells. Future studies include comparing the
localization of transcriptional complexes and viral dsRNA between macrophages and
other cell types.
It is possible that the endothelial cells that line the blood vessels and/or the ependymal
cells that line the ventricles of the brain may express relatively high levels of interferonstimulated genes, including Oas, and thus provide a barrier to viral entry into the brain
parenchyma that is bypassed by intracranial and intranasal inoculation. Indeed, while
MHV does not spread into the brain after peripheral inoculation in B6 mice, intrahepatic
inoculation readily produces encephalitis in mice impaired in type I interferon signaling
(either Ifnar1-/-or Ifih1-/- mice; unpublished data). Endothelial cells are mediators and
sensors of peripheral immune responses that connect and inform the CNS of immune
processes. Endothelial cells are in constant contact and crosstalk with blood circulation
and under continuous challenges. These cells are the first line defenders against CNS
attack and demonstrate an active role in CNS innate immunity (Danese et al., 2007).
Under physiological conditions, endothelial cells are immunologically quiescent, but
during an infection, bioactive molecules modulate BBB integrity (Laflamme et al., 1999;
Schiltz and Sawchenko, 2002) to facilitate immune cell migration into the brain
parenchyma. Furthermore, ependymal cells have been shown to express higher levels of
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Oas mRNA than other CNS cells in vivo (Asada-Kubota et al., 1997). Future studies will
be directed at investigating the possibility that one or both of these cells types may play
a gatekeeping role similar to the function proposed for KC in the liver and thus prevent
the spread of peripheral viral infections into the brain.
In conclusion, early protection of the host against viral infections relies on the rapid
detection of the pathogen and optimal activation of the type I IFN response. A cell
encountering type I IFNs in the absence of other cues will activate the classical antiviral
state by upregulating expression of interferon-inducible genes. These genes include
nucleic acid sensors like RIG-I and MDA5; increased abundance of these sensors would
make cells surrounding an infected cell more sensitive to detection of virus. However,
the induction of IFN and subsequent upregulation of ISGs through RIG-1 and MDA5
might be too slowly induced in infected cell types and whole organs. Data presented as
part of this thesis underscores the potential for OAS proteins to serve as nucleic acid
sensors that activate an RNA decay pathway and apoptosis though the use of RNase L.
This might allow the quick disposal of infected cells before the IFN response and
signaling cascade have begun. This process could spare neighboring infected cells from
infection.
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V
CHAPTER FIVE
EXPERIMENTAL FRAMEWORK AND NOTATION
Ethics statement. This study was in strict accordance with federal regulations set forth
in the Animal Welfare Act (AWA), recommendations in the Guide for the Care and Use
of Laboratory Animals of the National Institutes of Health, and the guidelines of the
University of Pennsylvania Institutional Animal Use and Care Committee. The protocols
were approved by the Institutional Animal Care and Use Committee at the University of
Pennsylvania.
Viruses, cell lines, and mice. Murine L2 fibroblasts were maintained in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum (FBS),
HEPES (10 mM), and 1% penicillin-streptomycin. Plaque assays were performed on L2
cells as described previously (Gombold, Hingley, & Weiss, 1993). Murine 3T3/pLZ
fibroblasts were grown in DMEM containing 10% FBS supplemented with G418 (350
µg/mL) and 1% penicillin-streptomycin (Zhou et al., 1998; Zhou, Paranjape et al. 1998).
The recombinant coronaviruses inf-MHV-A59 (wild type A59, referred to as A59 here)
and inf-ns2-H126R (referred to as ns2H126R here) were obtained from Dr. Stuart Siddell
(University of Bristol, Bristol, United Kingdom) and have been described previously
(Roth-Cross et al., 2009; Zhao, Rose, Elliott, Van Rooijen, & Weiss, 2011; Roth-Cross,
Stokes et al. 2009, Zhao, Rose et al. 2011). Newcastle disease virus expressing green
fluorescent protein (NDV-GFP) (Park et al., 2003; Roth-Cross, Bender, & Weiss, 2008;
Zhao et al., 2013; Park, Shaw et al. 2003, Roth-Cross, Bender et al. 2008, Zhao, Birdwell
et al. 2013) was obtained from Dr. Luis Martinez-Sobrido (University of Rochester School
of Medicine). C57BL/6 (B6) mice were purchased from the National Cancer Institute
(Frederick, MD). Rnasel-/- mice (bred for 10 generations to obtain a B6 background) were
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described previously (Zhou et al., 1997; Zhou, Paranjape et al. 1997). Ifih1-/- Gitlin,
Barchet et al. 2006) and Ifnar1-/- (Pinto et al., 2011; Pinto, Daffis et al. 2011) mice, both
with B6 background, were obtained from Dr. Michael S. Diamond (Washington
University in St. Louis, St. Louis, MO). Both strains were further bred and maintained in
the animal facility at the University of Pennsylvania.
Quantitative reverse transcribed PCR. RNA was isolated with an RNeasy minikit
(Qiagen, Valencia, CA). Quantitative real-time reverse transcriptase-PCR (qRT-PCR) was
performed as described previously (Zhao, Rose, Elliott, Van Rooijen, & Weiss, 2011).
Briefly, 200 ng (cells) or 350 ng (tissue) of total RNA was reverse transcribed into cDNA
using reverse transcriptase (Superscript III; Invitrogen) in a total volume of 20 μL. Then,
2 μL of cDNA was combined with 12.5 μL of iQ5 SYBR green mix (Bio-Rad, Hercules, CA),
6.5 μL diethyl pyrocarbonate (DEPC)-treated water, and 4 μL primer mix (5 μM each).
DNA was amplified using an iQ5 iCycler (Bio-Rad), and cycle threshold (CT) values were
recorded. Expression levels of mRNA were quantified as ΔCT values relative to β-actin
mRNA with the equation: 2-ΔCT, where ∆CT = (CT, Target Gene - CT, β-actin). Quantitative RT-PCR
primer sequences are available upon request.
Primary cell cultures. (i) Bone marrow-derived macrophages (BMM) were generated
from the hind limbs of B6 (WT), Ifih1-/-, or Ifnar1-/- mice as described previously
(Caamano, Alexander, Craig, Bravo, & Hunter, 1999; Casson et al., 2013; Zhao et al.,
2012{Casson, 2013 #47)(Caamano, Alexander et al. 1999, Zhao, Jha et al. 2012 {Casson,
2013 #47}, Casson, Copenhaver et al. 2013) and cultured in DMEM supplemented with
10% FBS and 30% L929 cell-conditioned medium for 6 days before infection. Cultures
were routinely ≥99% pure as assessed by positive staining for expression of CD11b and
negative staining for expression of CD11c. (ii) Bone marrow-derived dendritic cells
(BMDC) were generated from the hind limbs of WT mice as described by {Inaba, 1992
#46;Copenhaver, 2014 #108} and cultured in RPMI 1640 (Sigma-Aldrich) supplemented
with 10% FBS, 2 mM L-glutamine, 1% penicillin-streptomycin, 50 µM β95

mercaptoethanol, and 20 ng/mL of GM-CSF (Peprotech). The cells were fed on day 3, 6,
and 8 with fresh media and supplements. On day 10, cells were harvested and replated
at 200,000 cells/well using growth media with 5 ng/mL GM-CSF on 24-well non-tissue
culture treated plates and used for infections. Cells were routinely >95% CD11c+ and 80
to 90% immature (MHCIIlo). (iii) Hippocampal neurons were prepared from embryonic
day 15.5 (E15 to E16) mouse embryos as described previously (Bender & Weiss,
2010)(Bender & Weiss, 2010)(Bender and Weiss 2010). Briefly, cells were seeded onto
poly-L-lysine-coated tissue culture plates, cultured in neurobasal medium containing B27 supplement (Invitrogen), 1% penicillin-streptomycin, 2 mM L-glutamine, and 4 μg/mL
glutamate for 4 days in the absence of an astrocyte feeder layer and then used for
infections. Neuron cultures were routinely 95 to 98% pure, as determined by positive
immunostaining for MAP2 and negative immunostaining for CD11b (microglia-specific
marker), glial fibrillary acidic protein (GFAP) (astrocyte-specific marker), and OLIG2
(oligodendrocyte-specific marker) (Bender, Phillips, Scott, & Weiss, 2010)(Bender,
Phillips, Scott, & Weiss, 2010)(Bender, Phillips et al. 2010). (iv) Mixed glial cultures,
consisting of astrocytes and microglia, were generated from the brains of 1 to 3-day-old
neonatal mice as describe previously (Zhao et al., 2012; Zhao, 2012). Briefly, tissue was
dissociated by mechanical disruption through a 70 µm nylon mesh filter and plated in
complete medium consisting of DMEM supplemented with 10% FBS, 1% nonessential
amino acid solution, 2 mM L-glutamine, 1% penicillin-streptomycin, and 10 mM HEPES
and cultured for 9 to 11 days. These cells were lifted from their culture vessel using the
enzyme-free, Hank’s-based balanced salt solution cell disassociation buffer (Gibco). (v)
Astrocyte cultures were generated as described in (iv) and after 9 to 11 days in culture,
the flasks were shaken to remove nonadherent microglial cells, and the remaining
adherent cells were ≥95% pure astrocytes, as determined by positive immunostaining
for GFAP (Zhao et al., 2012)(Zhao et al., 2012)(Zhao, Jha et al. 2012) and used for
infection. (vi) Microglia cultures were generated from mixed glial cultures by collecting
the semi-adherent by shaking at 37 ˚C at 300 RPM for 30 minutes. (vii) Mouse primary
hepatocytes were isolated using a two-step collagenase perfusion technique involving
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sequential perfusion of the liver with EDTA and collagenase (Invitrogen). Hepatocytes
were plated on collagen-coated plates (BD Biosciences) in William E medium (Sigma), a
modified MEM used for long-term culture of adult liver epithelial cells, supplemented
with 10% fetal bovine serum and antibiotics. The cells were allowed to attach for 2 h
before switching to William E medium supplemented with 1% (vol/vol) nonessential
amino acids (3).
Infections of cell cultures. Virus was added to cells at a multiplicity of infection (MOI) of
1 PFU/cell and allowed to adsorb for 1 hour at 37 °C. Cultures were washed with PBS (3
times) and fed with medium as described for each cell type. The culture supernatants
were harvested at the times indicated for the specific experiments, and the titers were
determined by plaque assay on L2 cells. When indicated 3T3/pLZ or 3T3/neo, cells were
treated with 0 or 100 units/mL universal IFN-α for 4 hours. Then, poly(rI):poly(rC) [pIC],
(Invitrogen) was transfected at a concentration of 0 or 1 μg/mL using 0 or 3 μg/mL
Lipofectamine 2000 (Invitrogen) according to the manufacturer's protocol. Mock
transfected cultures were maintained in medium only. Cell lysates were harvested 12
hours after transfection to collect RNA.
IFNAR1 blocking antibody treatment. BMM cultures were treated with 0, 2, or 5 µg/mL
of IFNAR1 blocking mAb (clone MAR1-5A3, BD Sciences) or an isotype control (purified
NA/LE mouse IgG1 κ, clone 107.3, BD Sciences) for one hour at room temperature with
gentle agitation before virus infection or mock infection (Fenner et al., 2006).
Immunoblotting. Cells were treated with 0 or 100 units/mL of universal IFNα, for four
hours and then lysed in nonidet P-40 (NP-40) buffer (1% NP-40, 2 mM EDTA, 10%
glycerol, 150 mM NaCl and 50 mM Tris pH 8.0) containing protease inhibitors (Roche).
Protein concentrations were measured using a DC protein assay kit (Bio-Rad).
Supernatants were mixed 1:1 with 2X SDS-PAGE sample buffer. Samples were boiled,
separated by 10% SDS-PAGE and transferred to polyvinylidene difluoride (PVDF)
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membranes. Blots were blocked with 5% nonfat milk and probed with the following
antibodies directed against: OAS1A (clone E-2, Santa Cruz; 1:200), OAS2 (clone G-9,
Santa Cruz, 1:200), OAS3 (clone D-7, Santa Cruz, 1:200), mouse RNase L (clone T-16,
Santa Cruz, 1:200), mouse RNase L (rabbit polyclonal against mouse RNase L; 1:1000),
human RNase L (mouse monoclonal against human RNase L; 1:1000) (Dong & Silverman,
1995) as well as anti-GAPDH-HRP (Abcam, 1:4000), anti-β-tubulin-HRP (Abcam, 1:4000).
Anti-mouse IgG2a-HRP (Santa Cruz, 1:4000), and anti-rabbit IgG-HRP (GE Healthcare,
1:10000) secondary antibodies were used to detect the primary antibodies of the
appropriate species. The blots were visualized using Super Signal West Dura Extended
Duration Substrate (Thermo Scientific). In Figures 3.4G and 3.5D blots were probed
sequentially with antibodies directed against OAS1, OAS2, OAS3, RNase L, and GAPDH,
with blots being stripped between antibody treatments. In Figures 3.2D and 3.3B
parallel gels were run and blotted with individual antibodies.
Bioassay for antiviral activity. Supernatants recovered from cells that were infected
with MHV strains at an MOI of 1 PFU/cell were exposed to 600 mJoules•cm-2 UVA light
in a Stratalinker 1800 (Stratagene) to inactivate the virus. L2 mouse fibroblasts were
treated with the UV-inactivated supernatants for 24 hours and then infected with NDVGFP at an MOI of 1 PFU/cell as described previously (Park et al., 2003)Park, Shaw et al.
2003). Control cells were treated with 100 U/mL universal IFNα (Quansys Biosciences,
UT) for 24 hours before NDV-GFP infection. At 12 and 24 hours post infection, cells were
fixed in Dulbecco’s phosphate buffered saline (Gibco) containing 4% paraformaldehyde
and examined for enhanced-GFP (EGFP) expression under an Eclipse TE2000-U
fluorescence microscope (Nikon Instruments, Inc.). Images were acquired using NISElements Basic Research microscope imaging software (Nikon Instruments, Inc.).
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IFNβ quantification. IFNβ protein in supernatants of MHV-infected BMM was quantified
with a commercial capture enzyme-linked immunosorbent assay kit (VeriKine Mouse
Interferon Beta ELISA Kit, PBL Laboratories, Piscataway, NJ) according to the
manufacturer's instructions.
Ribosomal RNA degradation assay. For quantification of rRNA cleavage, total RNA from
virus-infected cells was isolated using an RNeasy kit (Qiagen) and quantified using a
Nanodrop analyzer. Equal amounts of RNA were separated on RNA chips and analyzed
with an Agilent 2100 Bioanalyzer (Agilent Technologies) as described previously (Xiang
et al., 2003; Zhao et al., 2012)(Xiang et al., 2003; Zhao et al., 2012)(Xiang, Wang et al.
2003, Zhao, Jha et al. 2012).
Immunoblotting. Cells were lysed in nonidet P-40 (NP-40) buffer (1% NP-40, 2 mM
EDTA, 10% glycerol, 150 mM NaCl and 50 mM Tris pH 8.0) containing protease inhibitors
(Roche). Protein concentrations were measured using a DC protein assay kit (Bio-Rad).
Supernatants were mixed 1:1 with 2X SDS-PAGE sample buffer. Samples were boiled,
separated by 10% SDS-PAGE, and transferred to polyvinylidene difluoride (PVDF)
membranes. Blots were blocked with 5% nonfat milk and probed with antibodies
directed against OAS1A (clone P-12, Santa Cruz; 1:500), OAS2 (ab197655, Abcam;
1:500), RNase L (rabbit polyclonal against mouse RNase L; 1:1000), RNase L (mouse
monoclonal against human RNase L; 1:1000 (Dong & Silverman, 1995)(Dong &
Silverman, 1995)(Dong and Silverman 1995) and GAPDH-HRP (ab9385, Abcam; 1:4000).
Anti-mouse HRP (1:4000 and anti-rabbit HRP (1:10000) secondary antibodies were used
accordingly. The blots were visualized using Super Signal West Dura Extended Duration
Substrate (Thermo Scientific).
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Quantifying IFNAR1 surface expression. BMM and mixed glial cultures were stained
with antibodies against GFAP (BD, clone 1B4), CD11b (eBioscience, clone M1/70), F4/80
(Biolegend, clone BM8), and the type I interferon receptor IFNAR1 (Leinco, clone MAR15A3) or an isotype control (Leinco, clone GIR-208). Staining for GFAP was conducted
following permeabilization with the Cytofix/cytoperm Plus Fixation/Permeabilization kit
(BD). Cells were analyzed with an LSR II (Becton Dickinson) and resulting data was
analyzed using FlowJo Software (Treestar). Astrocytes (GFAP+CD11b-F4/80-) and
microglia (GFAP-CD11b+F4/80+) from mixed cultures and macrophages (GFAPCD11b+F4/80+) from bone marrow derived cultures were assessed for surface
expression of IFNAR1 (Leinco, clone MAR1-5A3) or an isotype control (Leinco, clone GIR208).
Fluorescence intensity, dependent on both surface IFNAR1 density and cell surface area,
was normalized by cell size using previously described methods (Knijnenburg et al.,
2011). This allowed us to compare receptor density between cells of different sizes.
Briefly, forward scatter (FSC), a measure of cell volume, and side scatter (SSC), a
measure of cell granularity, were used in a linear least-squares regression model to
determine fluorescence intensities corrected for cell size and shape. Residuals from the
model represent the variability in fluorescence that is not due to cell size and cell
granularity. These residuals were offset by the sample-specific average fluorescence
intensity to calculate the final values. Calculations and analysis were performed with
MATLAB (Mathworks, Natick, MD).
Statistical analysis. Plotting of data and statistical analysis were performed using
GraphPad Prism software (GraphPad Software, Inc., CA) Statistical significance was
determined by the unpaired two-tailed Student's t test.
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